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1. INTRODUCTION 
 
This review is concerned with the role of fibrillization of the amyloid  (A ) peptide 
in Alzheimer’s disease (AD). The perspective is that of a physical chemist and one 
aim is to introduce relevant key findings on physico-chemical properties. However, in 
addition, key aspects of the biology and biochemistry associated with the role of A  
in AD are also summarized (more detailed reviews of these aspects can be found 
elsewhere),
1
 as are developments in potential therapies and biomarkers.  
 
The aggregation of the amyloid  peptide into oligomers or fibrils is now 
implicated as a key process associated with progression of AD.
2
 This is the focus 
of the current review. Whilst the protein tau has an important role in AD 
progression, its processing occurs downstream of A  accumulation.
3
 A marked 
decrease or absence of tau expression appears to reduce the neurotoxic effects of 
A .
4
 Proteins including NAC (non-beta-amyloid component) are also co-deposited 
along with A  in plaques.
5
 NAC comprises residues 61-95 of -synuclein, which 
is involved in amyloidoses with Lewy bodies such as Parkinson’s disease.  These 
topics are not discussed further herein, with the exception of a brief discussion 
(Section 2.8) of the interaction between A  and tau. 
 
Due to the very large number of papers on A  this review cannot be exhaustive in 
the space available. We have attempted to focus on key papers, and work that 
illustrates the main features of the subjects in the following sections. We have 
attempted to review work by many groups who have made important 
contributions. As there are also a large number of previous reviews on the topic of 
 5 
A  aggregation and its relationship to neurodegenerative disease, we can also only 
cite a number of the key earlier reviews here.
1,6
 
 
AD is the most common cause of dementia (representing around 50-80% of all cases
7
) 
with an estimated 18 million people worldwide currently affected by the condition 
(according to the World Health Organization).
8
 Its incidence increases dramatically 
with age, and the number of people with dementia is set to double in the next twenty 
years.
7
 The annual cost of dementia in the UK is estimated at £23 billion per annum 
including care and healthcare costs and lost productivity, which equates to £28k per 
patient.
9
 Alzheimer’s disease accounts for about 70% of all late-onset dementia 
cases.
10
 Most cases occur relatively late in life, although around 5% occurs in patients 
under 60 years old. These cases are termed early onset familial Alzheimer’s disease 
(FAD). Genetic mutations have been linked to these conditions as discussed in section 
2.1 below. In AD, neurodegeneration is estimated to start 10-30 years before clinical 
symptoms are detected.
2a,11
 
 
Intense research activity is focussed on the development of treatments for 
Alzheimer’s disease (AD) as discussed in Section 3. Several existing treatments can 
manage the condition but they do not arrest or reverse the progression of AD, i.e. 
there is no cure. A healthy diet and exercise may contribute to reduced AD risk as 
might enhanced mental activity and social engagement.
12
 Calorie restriction and 
intermittent fasting also ameliorate age-related behavioural deficits in transgenic 
mice.
13
 Further discussion of these epidemiological studies is outside the scope of the 
present review. A number of strategies to treat the condition are actively being 
pursued by research teams in academia and the pharmaceutical industry.
12a,14
 These 
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include (i) development of -secretase inhibitors ( -secretase is an enzyme involved in 
cleavage of amyloid  (A ) peptides from the Amyloid Precursor Protein), (ii) 
passive immunization based on A  antibodies (iii) inhibition of aggregation of 
oligomers. These are discussed further in Section 3.  
 
Susceptibility to AD increases with aging, as indicated by large population screening 
studies and studies using monkeys
15
 and transgenic mice.
15
 Much research has 
focussed on early-onset AD for which genetic markers and the role of A  are readily 
identified.
2c
 Table 1 shows characteristics of early-onset AD (EOAD). It is 
responsible for ~2% of cases and can occur as early as 30 years of age.
2c
 Late-onset 
AD (LOAD) is the more common variant that causes the majority of the cases of age-
dependent dementia. Age is the single biggest known risk factor, with the incidence of 
the disease increasing from approximately one in ten of those over 65, doubling 
roughly every five years to affect approximately half of individuals over 85.
2c,8,16
 
Susceptibility to LOAD also seems to have a genetic basis, although a single genetic 
determinant does not exist – several genes associated with susceptibility to the 
condition are known (as discussed further in Section 2.1) and a combination of genes 
may also be involved. The progression of AD is similar for EOAD and LOAD and is 
arbitrarily divided into early/mild, moderate and severe cases.  
 
Oxidative stress may play an important role in the age-dependent susceptibility to 
AD.
17
 Oxidative stress involves the production of free radicals (especially hydroxyl 
radicals) in the presence of metal ions, which can influence metabolism, and also 
promote A  aggregation, the latter subject being discussed further in section 4.8. The 
free radicals can cause increased lipid peroxidation, and the formation of associated 
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byproducts, as well as protein and DNA oxidation in the AD brain. Diminished 
mitochondrial energy metabolism may play a role in AD pathogenesis, due at least in 
part to reduced cyclooxygenase (COX) activity (section 2.1).
17
 Excitotoxicity is the 
overstimulation of N-methyl-D-aspartate (NMDA) or 2-amino-3-(5-methyl-3-oxo-1,2- 
oxazol-4-yl)propanoic acid (AMPA) receptors (NMDARs and AMPARs respectively) 
by glutamate or aspartate, leading to neuronal hyperexcitability and death. It can also 
generate excess reactive oxygen species (ROS). The role of oxidative stress is 
evidenced by the presence of protein glycation end products in A  aggregates, as well 
as an increase in the number of activated microglial cells (section 2.3).
17
 The 
inflammation that results from oxidative stress as well as A - (and tau-) induced 
neurodegeneration has an important role in AD pathology, as reviewed by the 
neuroinflammation working group.
18
 
 
Table 1. Characteristics of Early-Onset AD.
2c
 
Gene Age of onset, 
years 
A  phenotype 
APP trisomy 21 50s Total A  production increased 
APP mutations 50s Total A  production increased 
A 42/A 40 ratio increased 
APP triplication 
of APP gene 
50s Total A  production increased 
Presenilin 1 40s and 50s A 42/A 40 ratio increased 
Presenilin 2 50s A 42/A 40 ratio increased 
 
Diagnosis of AD is usually through cognitive testing methods detailed elsewhere,
2c
 
supported by scanning techniques such as magnetic resonance imaging (MRI). 
However, research into biomarkers is a very active and promising field (section 2.4). 
Prior to development of AD, patients may suffer mild cognitive impairment (MCI), 
and around 40-60% of patients with this condition develop AD within five years.
19
 
 8 
Factors that can be used to track the risk of progression of AD have recently been 
reviewed, leading to guidelines for the preclinical assessment of the condition.
20
  The 
pathogenic process leading to AD may start many years (a period of approximately 
one decade has been identified
20
) before obvious symptoms are noted. The 
development of biomarkers at an early stage of disease progression would be 
extremely beneficial.  
 
The insulin/insulin growth factor (IGF) signalling pathway influences ageing and AD 
progression, as discussed further in section 2.1. Genes undergoing age-related 
changes in expression have been identified, as have markers of mitochondrial 
dysfunction in response to oxidative stress.
21
 Another vital regulator of the aging 
process is autophagy (degradation of intracellular components through lysosomes). 
Increased autophagy extends lifespan due to reduced insulin-like signalling and it may 
be stimulated by calorie restriction. Reduced autophagy leads to neurodegeneration, 
accompanied by the accumulation of ubiquitinylated protein aggregates.
21
 This can 
occur during normal ageing, but reaches pathological levels in neurodegenerative 
disorders such as AD. Proteasome dysfunction leads to increased levels of 
ubiquitinylated protein and to memory deficits in transgenic mice.
22
 
 
The pathology of AD comprises neuritic amyloid plaques and neurofibrillary 
tangles in the hippocampus, amygdala and association neocortex. Diagnosis with 
100% accuracy can only be achieved post mortem, however diagnosis with 95% 
accuracy is possible in living patients using a combination of tools including 
cognitive testing, brain imaging and analysis of family health history.
12a
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The A  hypothesis (Fig.1) implicates A  as a key causative agent of AD. 
Controversies surrounding the A  hypothesis, including the apparently paradoxical 
presence of A  deposits in the brains of people not suffering from dementia, and the 
cause/effect nature of A  deposition, have been discussed.
3,6e,23
 However, these 
deposits are diffuse and have none of the characteristic surrounding neuritic and glial 
cytopathology found in mature neuritic plaques.
6e,24
 Biochemical assays such as 
ELISA and Western blotting indicate that levels of soluble A  correlate better with 
the presence and extent of cognitive defects than simple plaque 
counts.
25
 
Fig.1. Amyloid cascade hypothesis of AD.
26
 Reprinted by permission from 
Macmillan Publishers Ltd: Nature Reviews Neurology 6, 131, copyright 2010. 
 
 
 10 
The term amyloid refers to protein deposits resembling those first observed for starch 
(amyloid originally meaning starch-like). It is now specifically associated with 
proteins and peptides adopting fibrils based on the cross-  structure in which the 
peptide backbone is orthogonal to the fibril axis.
27
 The -sheets form fibrils, which 
have an internal structure such as parallel protofilaments, and the fibrils themselves 
can further aggregate into larger fibres or bundles (which often comprise twisted 
fibrils).
6b,27d
 Figure 2 shows representative fibril morphologies for A  peptides, the 
fibril morphology depends on preparation conditions, and fibril polymorphism is also 
observed and examples of other fibril structures are shown in section 4.1. 
 
(a)      (b) 
  
Fig.2. “Typical” A  fibril morphology by TEM, obtained from incubated 50 M 
solutions of (a) A 40, (b) A 42.
28
 
 
Figure 3 shows a timeline of some of the principal discoveries in AD research, 
3,29
 
also the subject of other historical overviews.
2a,6e,30
 AD is named after Alois 
Alzheimer who first described the condition now named after him in 1906.
2a,31
 It is 
generally acknowledged that the first paper to identify A  in association with 
neuropathology was by Glenner and Wong in 1984,
32
 who identified a 4 kDa major 
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component of A  extracted from the blood vessels of a patient with Down’s 
syndrome. By middle age, the brains of Down’s syndrome patients inevitably display 
the neuropathological features of AD, i.e. deposition of A  plaques and AD-type 
brain lesions, although mental retardation from birth is due to other causes. Glenner 
and Wong were also able to sequence the first 28 amino acids of A . In the late 
1980’s, several different groups were able to use Glenner and Wong’s A  sequence to 
clone the gene encoding amyloid precursor protein (APP) and map it to chromosome 
21.
10,33
 Chromosome 21 is duplicated in Down’s syndrome, hence the correlation with 
A  deposition which occurs early in this condition. 
 12 
 
Fig.3. Timeline of selected AD discoveries including those associated with the A  
hypothesis.
3
 Reprinted by permission from Macmillan Publishers Ltd: Nature 
Medicine 17, 1060, copyright 2011. 
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There are two principal variants of the amyloid peptide in humans – A 40 and A 42 
(this notation will be used consistently for the whole peptide with the number of 
residues indicated, for fragments the sequence will be indicated).
1a
 The former is 
more abundant, however A 42 forms fibrils more rapidly.
1a,6d,34
 A 43 is also 
observed
35
 as are peptides truncated at the C terminus
36
 such as A 39.
37
 N-terminal 
truncated peptides are also detected.
36,38
 Tryptic degradation of A  from AD patient 
brains also revealed heterogeneous fragments from the A (1-5) and A (6-16) 
domains.
36
  
 
It is now thought that oligomers formed in the initial self-assembly process are the 
toxic agents.
2a,2d,39
 This is discussed in more detail in Section 2.6. Oligomerization of 
A  occurs intracellularly, as revealed by in vivo experiments on human cerebrospinal 
fluid which yielded SDS-stable dimers of A .
40
 Incubation did not lead to the 
production of extracellular oligomers. However, oligomers were detected in neural 
and non-neural cell lines. The importance of intracellular A  production and its 
relationship to extracellular production, and re-uptake has been discussed.
41
 Whether 
intra- and inter- cellular pools of A  are distinct or related has been the subject of 
studies with contradictory conclusions. However, it does appear that extracellular A  
may originate from intraneuronal sources, and a dynamic equilibrium may exist 
between these pools.
41
 Since A  is produced via cleavage of APP in membranes 
(Section 2.2.3) its sites of production include the plasma membrane, but also within 
the cell in the Golgi and endoplasmic reticulum, as well as endosomes and 
lysozomes.
41
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There is a relationship between the incidence of AD and cerebral ischemia (reduction 
in blood supply), eg. following a stroke or other cerebrovascular or cardiovascular 
condition.
42
 Oxidative stress, eg. hypoxia (oxygen deprivation) or ischemia may cause 
an increase in A  levels in the brain due to an upregulation of APP processing.
43
 A 
correlation between serial brain interstitial fluid (ISF) concentration and neurological 
status (after acute injury) has been noted, A  concentration increasing with improved 
neurological status.
44
 
 
Amyloid  is produced by proteolytic cleavage of APP, a transmembrane protein 
discussed further in Section 2.2.3.
2a
 The peptide N terminus is created by cleavage by 
-secretase in the extracellular domain of APP, and the C-terminus results from 
intramembrane cleavage by -secretase. A third enzyme, -secretase cleaves between 
amino acids 16 and 17 in A , thus hindering fibrillization. The cleavage by -
secretase is presenilin-dependent.
45
 As discussed further in Section 2.2.3, -secretase 
is a protein complex involving presenilins, nicastrin, APH-1 and PEN-2, all of which 
are required for γ-secretase function.46 Selkoe thoroughly reviews the historical 
literature concerning the relationship between the presenilins and -secretase.
1a
 
 
Whilst there have been numerous reviews on the amyloid hypothesis of AD, there are 
few up-to-date reviews that also discuss the biophysical aspects of A  self-assembly 
and its influence on AD. The present review aims to provide a unified view of the 
biological, neurochemical and biophysical aspects of A  aggregation and its 
relationship to AD. In addition, this review provides a current overview of 
developments in potential therapeutic strategies. 
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This review is organized as follows. The first section concerns the features of AD and 
the properties of A and APP in vivo, including biological and neurochemical 
characteristics. The development of biomarkers is also considered. This is followed 
by discussion of therapeutic compounds. The final sections are focussed on different 
aspects of the biophysical properties of A . 
 
2. BIOLOGICAL, BIOCHEMICAL AND NEUROCHEMICAL 
CHARACTERISTICS OF AD, INVOLVING A  AND APP 
 
2.1 Genetic Markers for AD 
2.1.1 Genetic Risk Factors 
Several genes have been linked to late-onset Alzheimer’s disease, most importantly 
the gene encoding apolipoprotein E (APOE)
47
, especially the 4 allele.
47a,47b,47d,48
 This 
is believed to cause the aggressive form of AD with earlier onset.
3,49
 APOE (and 
related APOC1) diagnostic testing systems have even reached the market although 
some products have been withdrawn due to IP issues.
50
 The compound rosiglitazone 
may ameliorate neuronal dendritic spine loss caused by ApoE- 4, and thus improve 
cognition in AD patients.
51
 
 
Mutations in the genes for APP,
52
 presenilin 1 and 2 (PSEN1 or PS1 and PSEN2 or 
PS2)
1a,53
 have a role in hereditary forms of AD.
54
 Dominantly inherited forms 
represent only 1-3% of the total number of cases of AD, most of which are 
sporadic.
2a,11,54
 Mutations in PS1 and PS2 potentially account for a large fraction of 
early-onset cases of familial AD.
1a,55
 Mutations in the presenilins cause an increase in 
A 42 in AD patients
1b,55a,56
 and also transfected cell lines and transgenic animals 
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expressing mutant forms of PS1 or PS2.
57
 and this occurs selectively for A 42/43 
over A 40.
56-57
 Certain presenilin mutations can disrupt the leakage of calcium (see 
the discussion of the calcium channel hypothesis in section 2.7) induced by 
presenilins from the endoplasmic reticulum leading to supranormal release and 
dyshomeostatis.
58
 This has been investigated in electrophysiology experiments.
55b,58-59
 
Missense mutations in PS1 are associated with early and aggressive forms of AD,
1a
 
A 42 plaques being observed as early as 3-4 months.
60
 The G209V, A260V and 
E280A presenilin A mutations lead to substantial overexpression of A 42 in the 
brains of FAD patients.
61
 Mutations in PSEN1 are also associated with acne inversa 
although a correlation between this condition and AD has not been noted.
62
  
 
The gene encoding ApoE was the first confirmed susceptibility locus for sporadic late 
onset AD, and its alleles have been widely studied. A recent study using microdialysis 
in a PDAPP/TRE mouse model (to be discussed shortly) indicates that different 
isoforms of the gene differentially regulate A  clearance from the brain.
63
 A genome-
wide association study identified three other loci, within CLU (which codes for 
apolipoprotein J, ApoJ or clusterin),
54,64
 within CR1 (complement receptor 1)
54
 or 
within PICALM.
64
 Single nucleotide polymorphs (SNPs) at these loci (as well as 
APOE) were associated with AD risk. ApoE and CLU are the most abundantly 
expressed apolipoproteins in the central nervous system.
54
 Earlier work had shown 
that ApoJ is over-expressed in individuals with AD and is present in CSF
65
 and 
amyloid plaques.
66
 Clusterin binds soluble A  to form complexes (especially with the 
more toxic A 42 peptide) which can cross the blood-brain barrier.
67
 It promotes 
amyloid plaque formation and is critical for toxicity towards neurons.
68
 Bell et al. 
performed studies on the clearance of radiolabelled (
125
I) A  using a mouse model 
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and found that A 42 is cleared more slowly than A 40 and that A , ApoE and ApoJ 
(detected using human-specific ELISAs) are cleared from the brain by different 
transport mechanisms.
67b
  
 
A study using a yeast model has identified genetic factors influencing A  toxicity, 
including PICALM but also other previously unidentified genes associated with 
protein trafficking, stress and metabolism.
69
 This work also confirmed the effect of 
PICALM on A  toxicity using a C. elegans model and also using rat cortical 
neurons.
69
 In terms of mechanisms, the authors suggested that A  affects the 
endocytic trafficking of a plasma membrane receptor. Another genome-wide survey 
revealed an association between late-onset AD in carriers of the APOE- 4 allele and 
SNPs from the GRB-associated binding protein 2 (GAB2) gene.
70
 ApoD has also been 
associated with AD, this lipoprotein circulates as a components of serum high density 
lipoproteins (HDL) and may be involved in cholesterol transport.
71
 Apolipoprotein D 
is involved in lifespan extension in Drosophila, conferring resistance to oxidative 
stress, and its expression is induced in the AD brain.
71
  
 
Another gene that was identified as a risk for AD is CALHM1 (denoting calcium 
homeostasis modulator 1).
72
 The CALHM1 protein is localized in the cell membrane, 
and increased expression leads to enhanced calcium levels within the cytoplasm. 
Single nucleotide polymorphism of the gene leads to changes in AD susceptibility, 
specifically a P86L substitution leads to increased A  levels. However, these findings 
have been challenged – Bertram et al. also examined several family-based datasets 
and number of prior genome-wide association study (GWAS) datasets
70,73
 and found 
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no correlation between CALHM1 and AD.
74
 However, the authors of the original 
study dispute this analysis.
75
  
 
The role of the Orphan G protein-coupled receptor (GPR3) as a modulator of A  
production has recently been identified.
76
 The GPR3 gene has been mapped to a 
candidate AD linkage region in one chromosome as part of a large-scale genome 
screen using an NIMH (National Institute for Mental Health) sample.
77
 GPR3 
expression leads to an increase in production of the -secretase complex, and its cell 
surface localization, in the absence of an effect on Notch processing (discussed 
further in Section 3.2.1).
76
 Notch proteins are transmembrane proteins involved in 
development and signaling pathways and a key challenge in the development of 
effective -secretase inhibitors is to avoid side effects caused by interference with 
these pathways. GPR3 was found to be highly expressed in areas of the normal brain 
implicated in AD and is elevated in the sporadic AD brain. It thus represents a 
potential target for therapeutic treatment. 
 
Other proteins associated with A  production or APP processing include the serotonin 
receptors
78
 and the prostaglandin EP2 receptor.
79
 Prostaglandin E2 is produced during 
inflammation due to activity by cytosolic phospholipase A2 (PLA2) or 
cyclooxygenase 2 (COX-2). 
79
 The latter enzyme is upregulated in AD brain frontal 
cortex and synthetic A  peptides induce COX-2 expression in SH-SY5Y 
neuroblastoma cells in vitro.
80
 COX-2 is involved in the inflammatory response and is 
the target of NSAIDS (non-steroidal anti-inflammatory drugs). A population-based 
study pointed to the elevation of serum levels of pregnancy zone protein (PZP) in pre-
symptomatic AD, compared to controls.
81
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Genome-wide studies of genes associated with aging indicate that the insulin/IGF-1 
signalling pathway may be involved in Alzheimer’s. Reduced signalling causes 
decreased AD pathology in mice
82
 while paradoxically increased signalling may also 
be neuroprotective.
21
  
 
2.1.2 Transgenic Mice 
Many studies use the PDAPP mouse, also known as PDGF-hAPP (from platelet-
derived growth factor) mouse, which overexpresses mutant human APP (V717F 
mutant) under control of mouse regulatory elements and leads to A  plaque 
deposition.
15,83
 The PDAPP/TRE model expresses human ApoE. The TgCRND8 
murine model of AD expresses a doubly mutant (K670N/M671L and V717F) human 
APP695 transgene.
84
 Tg2576 APP mice expressing the Swedish FAD variant of 
human APP695 (section 2.2.3)
85
 which leads to a selective increase in A 42/43 
production have also been used in A  immunization experiments.
86
 Tg2576 mice 
develop memory deficits due to the extracellular accumulation of specific A  
oligomeric species, i.e. dodecamers.
87
 A doubly mutant transgenic mouse including 
the APP(Swe) and mutant PS1 (M146L) has been developed and exhibited a large 
selective enhancement of A 42 and plaque deposition.
60
 The 3xTg model in a triply 
transgenic mouse contains PS1(M146V), APP(Swe), and tau(P301L) transgenes
88
 and 
this has been used to investigate the interplay of A  and tau (neurofibrillary tangles) 
pathologies (section 2.8). Contrary to doubly transgenic mice lacking the APP 
transgene, deposition of plaques and synaptic dysfunction (LTP deficits) are observed 
with the 3xTg model.
88
 The APP23 mouse overproduces A 40 and the APPPS1 
mouse overexpresses A 42.
89
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2.2 A  in vivo 
2.2.1 Characteristics of A  in vivo 
 
Evidence that the A 42 form of A  is the variant preferentially implicated in AD 
comes from several sources. Studies of the kinetics of aggregation (through turbidity 
measurements) indicate that A 42 nucleates more rapidly and is more fibrillogenic 
than A 40.
34,90
 The toxicity of A 42 is much greater than A 40
91
 due to its greater 
tendency to fibrillise. Some mutations in APP in cultured cells (discussed in section 
2.2.2) lead to increased levels of  A 42, whereas wildtype APP predominantly 
releases A 40.
92
 It is also found that A 42 is the principal component of diffuse A  
plaques and plaques generated from APP mutants
93
 and in homogenized brain 
tissue,
94
 and that early and selective deposition of A 42 is observed in the brains of 
AD patients (shorter peptides with different N termini are also found).
36,38
 Despite its 
lower toxicity, A 40 is actually produced by a factor of ten times more than A 42, by 
-secretase cleavage.
41
 
 
Whilst A  is generally associated with disease, a functional role for the peptide has 
also been suggested. Tanzi and coworkers have demonstrated that it is an 
antimicrobial peptide, i.e. that it is involved in immune reactions.
95
 Antimicrobial 
activity of A 40 and A 42 has been demonstrated against eight common 
microorganisms including E. coli and S. aureus. This activity can be blocked by 
immunodepletion of AD brain homogenates with anti-A  antibodies.
96
 Temporal lobe 
tissue from AD patients showed higher antimicrobial activity than material from the 
 21 
brains of age-matched non-AD subjects. Balin’s group have suggested that A  may 
be part of the control mechanism following infection by C. pneumoniae,
97
 and that it 
can mediate infection of cells with this bacterium.
98
 Smith and coworkers argue that 
A  production is a host response to an underlying condition that develops with age.
99
 
However, this is becoming an increasingly contrarian viewpoint in view of the mass 
of data implicating A  as the causative agent. The 4 allele of the APOE gene, a 
marker for EOAD (section 2.1.1) may have a beneficial role in enhanced cognitive 
skills.
100
 
 
The fraction of different variants of A  has been investigated. Based on analysis of 
cell lysates and also tissue from mouse brain, A 40 has been found to constitute 
approximately 90% of the secreted A  and A 42 comprises ~10%,
57b-d
 although 
somewhat lower
57c
 and much higher
57e
 fractions have also been reported. A 42 is the 
most commonly found variant in human CSF. 
 
Since APP is expressed in most peripheral cells, A  is present in plasma in addition to 
CSF. The level of A 40 in plasma is generally under 200 pM, and of A 42(3) is 
under 60 pM, although both are elevated in patients with PS1 or PS2 mutations or in 
patients with presymptomatic or symptomatic APP patients.
56
 The physiological 
concentration of A  (in AD patients) in human CSF has been reported by several 
groups.  An A  concentration of less than 500 pg/ml (0.1 nM) is indicative that A  is 
accumulating in the brain and not circulating in the CSF. Using an ELISA assay, 
Mehta et al. reported for A 40 c = 30 nM.
101
 and for A 42 c = 8 pM.
101
 On the other 
hand, Ida et al. using a Western blot assay reported a lower c = 6 nM for A 40 but a 
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much higher c = 60 pM for A (1-42).
37
 Similar values for A 42 for AD patients are 
reported by Motter et al.
102
 Values in plasma are also available.
56,101
 The CSF 
concentration of A 40 for AD patients is not significantly different to that for 
nondemented control patients, however the concentration of A 42 is lower for AD 
patients.
37,101-102
 This is another evidence for A 42 as the disease-related species. 
Peripheral adminstration of monoclonal antibodies leads to a rapid increase in plasma 
A .
103
 The physiological concentration of A  (variant not defined) in normal human 
CSF is around 1- 2 nM according to ref.
104
 whereas a value of 3-8 nM is cited 
elsewhere.
1a,102
 According to Podlisny et al. the physiological concentration of A 40 
is 0.25 – 2.5 nM,105 in agreement with the value c = 0.6 nM reported by other 
groups.
106
 There is no correlation between plasma A 40 and A 40 load (in the range 
0-40% for 46 nM A 40 in PDAPP mouse plasma) in the absence of anti-A  
antibodies.
103
 The concentration of A  in serial brain interstitial fluid has also been 
reported.
44
 Ida et al. also detected the presence of N-terminally truncated A  species 
in CSF and plasma.
37
 
 
The production of A 40 and A 42 in the human central nervous system (CNS) does 
not appear to be different for AD patients compared to control, however the rate of 
clearance is significantly reduced for AD patients.
107
 Production of A  is discussed in 
the following section. Low-density lipoprotein receptor-related protein (LRP) and the 
receptor for advanced glycation end products (RAGE) are involved in receptor-
mediated flux of A  across the BBB as part of the clearance mechanism.
108
 Clearance 
of A  from the brain to the periphery appears to be mediated by LRP while RAGE is 
implicated in A  efflux back into the CNS (Fig.4).
108b
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Fig.4. Clearance mechanisms of A  involving LRP and RAGE.
108b
 Blocking 
interaction of A  with zinc and copper may clear A . Soluble A  can be removed via 
enzymatic degradation (via peptidases such as insulin degrading enzyme IDE or 
neprilysin NEP, and subsequent degradation by activated microglia) or receptor-
mediated clearance. LRP receptor-mediated clearance can occur by direct binding or 
initial binding to the LRP ligands/A  chaperones ApoE and 2M which can deliver 
A  to peripheral sites of degradation (liver or kidney). These chaperones can also 
deliver A  across the BBB into the brain. This process can also occur via the RAGE 
receptor. Green arrows show pathways that might be pharmacologically relevant. 
Reprinted from Tanzi, R. E. et al., Neuron 2004, 43, 605, Copyright 2004, with 
permission from Elsevier 
 
2.2.2. Modelling AD and A  Deposition in Other Organisms 
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AD can be modeled using a variety of organisms including fruit flies (Drosophila 
melanogaster),
109
 nematode worms (Caenorhabditis elegans),
69,110
 potatoes,
111
 and 
yeast (Saccharomyces cerevisae).
69,112
 C. elegans has attracted particular attention  as 
a model to study the function of presenilins, especially in relation to Notch (Section 
3.3) since there are great similarities between the sel-12 gene of C. elegans and 
presenilin genes.
1a,113
 Drosophila melanogaster has been engineered to express both 
wild type human and arctic mutant A 42.
109d
 Yeast exhibits -secretase activity on 
APP.
112
 The later study showed that yeast can be used to model links between A , 
endocytosis and human AD risk factors.
69
 A (M1-40) and A (M1-42) i.e. with an N 
terminal methionine substitution, can be expressed in E. coli.
28,114
 The fibrils formed 
by the recombinant peptides are indistinguishable than those from chemically 
synthesized peptides. 
 
2.2.3 APP and the Production of A  
 
APP belongs to the family of type 1 transmembrane glycoproteins.
115
 It has been 
hypothesized to act as a vesicular receptor for the motor protein kinesin-I.
109b
 The 
production of A  in the amyloidogenic pathway involves the sequential cleavage of 
APP by -secretase and -secretase (Fig.5). The enzyme -secretase is an integral 
membrane aspartyl protease encoded by the -site APP-cleaving enzyme 1 gene 
(BACE1)
1a,1b,116
 while -secretase is a membrane-bound protease complex consisting 
of at least four components including the presenilins (PS1 and PS), nicastrin, and the 
genes APH-1 and PEN-2.
110b,117
  The -secretase complex may also function as an 
aspartyl protease.
1a,117b
 It has been proposed that A  up-regulates its own production 
by increasing BACE1 expression,
118
 possibly involving oxidative stress.
119
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Fig.5. Mutations in APP associated with A  production and expression and AD. 
Redrawn from ref. 
1a
 Secretase enzymes are indicated in blue, with cleavage sites 
arrowed. APP sequence numbers are shown in red, A  in purple. Mutants are 
indicated with green letters.  
 
 
In the non-amyloidogenic pathway, a third enzyme, -secretase cleaves between 
amino acids 16 and 17 in A , thus hindering fibrillization of the full peptide. The -
secretases belong to the “A Disintegrin and Metalloprotease” (ADAMs) family of 
zinc metalloproteinases.
120
  
 
Recent work suggests that in late onset Alzheimer’s disease, A  accumulation occurs 
intracellularly in late endosomes where enzymes -secretase and -secretase cleave 
A the latter in a presinilin-dependent fashion.
121
 The intracellular sites of A  
production occur where APP is located, as shown in Fig.6.
41
 The gene involved in 
APP recycling in endosomes has been identified, and is termed SORL1 and the 
associated protein is SORLA or LR11. Normally the protein product of the gene 
directs APP into recycling endosomes (retromer recycling endosomes, Fig.6), 
however mutations produce a decrease in protein product which leads to the pathway 
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where A  production via fragment C99 is increased by enzymes in the late 
endosomes.
121
 It has been reported that the proteolytic processing of A  is regulated 
by glycogen synthase kinase-3 isozymes,
46
 however this has been disputed.
122
  
 
 
Fig.6. Sites of intracellular A  production.
41
 A  is produced within the endoplasmic 
reticulum (ER) and Golgi system and secreted. APP is localized in the plasma 
membrane, where it is cleaved by -secretase, releasing soluble APPs into the 
extracellular space and leaving an 83-amino acid fragment known as C83 within the 
membrane. Unprocessed APP can be internalized into early endosomes. In the 
presence of SORL1, APP is recycled back to the Golgi in retromer endosomes. Early 
endosomes contain BACE1 which cleaves APP to produce a 99 residue fragment 
C99, retained within the membrane. C99 can be shuttled back to the ER to be 
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processed into A  by -secretase in the ER, shuttled back to the plasma membrane 
where the -secretase complex is also found, or processed to A  within the 
endosome/lysosome system. Extracellular A  (i.e. previously secreted A ) can bind 
to cell surface receptors (including RAGE, LRP, FPRL1, NMDA receptors and 7-
nAChR) and the receptor-A  complex can be internalized into early endosomes 
[FPRL1 denotes FMLP-receptor-like protein, NMDA denotes N-methyl-D-aspartate 
and 7-nAChR the 7 nicotinic acetylcholine receptor]. Intracellular accumulation of 
A  mainly occurs in the multivesicular body (MVB) and lysosome, but also in the 
mitochondria, ER, Golgi and cytosol, where it can influence proteasome function. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Neuroscience 8, 499, copyright 2010. 
 
 
In addition to the known isoforms of A , i.e. A 42, A 40 and A 38, shorter 
fragments have been identified in CSF.
120b
 This suggested a different APP processing 
pathway involving concerted cleavage of APP by - and -secretases. 
 
It has recently been proposed that rather than A , another APP fragment may be 
involved in AD (possibly along with A ).
123
 The N-APP extracellular N-terminal 
fragment is adjacent to A  and is also cleaved by BACE. It triggers the cell death 
cascade by binding to a neuronal receptor called DR6 (death receptor 6), which is 
highly expressed in regions of the human brain most affected by AD, in the presence 
of caspase 6.
123
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Fig.5 summarizes the mutations in APP linked to AD. It is notable that these 
mutations are located just outside the cleavage sites of - and -secretase beyond the 
N- and C-termini of A  respectively, as well as close to the -secretase cleavage site 
within A . Mutations within A  are expected to enhance the aggregation properties, 
and this has been shown for the E693Q mutation (Dutch-type) (Table 2, section 
2.2.4). The Flemish A692G mutation leads to a mixture of A  plaque and tangle 
formation as well as microvascular -amyloidosis and cerebral hemorrhage due to 
cerebral amyloid angiopathy.
124
 This mutation also enhances the proportion of APP 
cleaved by the -secretase homologue BACE-2.
1a,125
 
 
APP comprises a group of ubiquitously expressed polypeptides migrating between 
110 and 135 kDa on electrophoretic gels.
1a,126
 The heterogeneity arises since there are 
three main isoforms of human APP with 695, 751 and 770 residues, and additionally 
due to post-translational modifications including N- and O-glycosylation, 
phosphorylation and sulfation. APP forms containing 751 and 770 residues are widely 
expressed both in neuronal and non-neuronal cells throughout the body whereas the 
695-residue form is expressed more highly in neurons, and occurs at very low 
abundance in other cells.
1a
 The 751 and 770 isoforms contain a KPI (Kunitz-type 
Protease Inhibitor) domain (Fig.7) and are thus able to inhibit serine proteases such as 
trypsin and -chymotrypsin.
127
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Fig.7. Processing routes of APP to produce A  and other peptide fragments (C83, 
C99 and p3) as well as the soluble APPs ectodomain fragments. Redrawn, based on 
schematics by Selkoe.
1a,1b
 TM denotes transmembrane domain, KPI denotes Kunitz-
type inhibitor domain which is a spliced exon of 56 amino acids inserted at residue 
289. Cleavage of both C83 and C99 C-terminal fragments by -secretase releases the 
-amyloid precursor protein intracellular domain (AICD) into the cytoplasm. A 17-
residue single peptide is indicated at the N terminus. 
 
Table 2 presents common mutations in APP. The E693Q mutation was the first to be 
associated with disease, hereditary cerebral haemorrhage with amyloidosis, Dutch 
type (HCHWA-D).
128
 The A692G Flemish mutation is associated with cerebral 
haemorrhage with amyloidosis (CHWA).
128
 A mutation in APP K670M671  
N670L671 has been associated with the so-called Swedish FAD.
129
 The London 
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variant involves V717I. 
52,128,130
 Detailed information on mutations in presenilins is 
provided elsewhere.
10,58a
  
 
Table 2. Effect on A  of APP mutations. Adapted from refs.
10,131
 
Name/FAD variant Mutation Effect on APP Effect on A  
APP-717 (London) V717F/G/I Differential -
secretase cut 
A 42:A 40 ratio 
increased 
APP-670/671 
(Swedish) 
K670N and 
M671L 
Increased -
secretase cut 
Increased A 40 
and A 42 in plasma 
APP-692 (Flemish) A692G Decreased -
secretase cut? 
Decreased A 40 
and A 42 in media, 
decreased A  
aggregation, 
A 42:A 40 ratio 
increased 
APP-693 (Dutch) E693Q Unclear Decreased A 42 in 
media, increased 
A  aggregation, 
A 42:A 40 ratio 
decreased 
APP-693 (Arctic) E693G
131
 Unclear Decreased A 40 
and A 42 in 
plasma,  
A 42:A 40 ratio 
decreased 
APP-693 (Italian) E693K
131
 Unclear Decreased A 42 in 
media, A 42:A 40 
ratio decreased 
APP-694 (Iowa) D694N Unclear Enhanced 
fibrillization of 
A 40
132
 
PS1-FAD mutations M139I, 
H163A, and 
others
55a
 
Differential -
secretase cut 
A 42:A 40 ratio 
increased 
PS2-FAD mutations  Differential -
secretase cut 
A 42:A 40 ratio 
increased 
Trisomy 21 (Down’s 
syndrome) 
 Increased APP 
production 
A 40 and A 42 
increased 
Apolipoprotein E4  Competes for LDL 
receptor-related 
protein (LRP) 
Increased A  
aggregation 
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Overexpression of the mutant V717F leads to neuronal cell death, and damage to 
synapse termini, well before the development of amyloid plaques.
15
 A double mutant 
transgenic mouse model also expressing the Swedish FAD mutant led to synapse 
transmission deficits even in young mice without amyloid plaques. These 
observations suggest that neurotoxicity of A  is independent of plaque formation, 
consistent with the neurotoxic agent being other species such as oligomers as 
discussed in section 2.6.1.
15
  A mutation M67I is found to eliminate production of 
A 42.
133
 High levels of A 42 result in age-dependent formation of amyloid plaque in 
FAD-mutant hAPP mice, but not in wild-type hAPP mice.
133
 There is no correlation 
between synapse damage and hAPP levels or plaque load, although there is an inverse 
correlation with A  levels. This points to the neurotoxicity of A  even in the absence 
of plaques.
133
 
  
A  is produced from APP via cleavage by the secretase enzymes. APP is a 
transmembrane protein that is postranslationally modified through the secretory 
pathway. The first proteolytic cleavage identified is that by -secretase, occurring 12 
amino acids towards the N terminus from the transmembrane domain (Fig.7).
1a
 This 
cleavage produces the large soluble -APPs peptide into the extracellular space, along 
with release of the 83-residue C-terminal fragment (CTF) in the membrane. Some 
APP molecules not subjected to -secretase cleavage can be cleaved by -secretase 
releasing the slightly smaller -APPs ectodomain derivative and retaining a 99-
residue CTF (C99) in the residue of the membrane. The -secretase cleavage can be 
followed by -secretase activity to produce A , or alternatively sequential action of - 
and -secretases (the latter acting on C83) produces the p3 peptide fragment (Fig.7).
1a
 
The presenilin/ -secretase complex can cleave at other sites  and  in the 
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transmembrane domain followed by the final cut at the -cleavage C-terminal site to 
produce A 38, A 40 or A 42.
6e
 
 
2.2.4 A  Mutations 
Strong evidence for the A  hypothesis comes from genetic analyses of FAD (Section 
2.2.3), since most mutations in the genes for APP, and PS1 and PS2 genes appear to 
cause accumulation of the A 42 form.  
 
The following mutations of A  are derived from those for APP (section 2.2): 
91a,134
 
A21G Flemish, E22K Italian, E22Q Dutch, E22G arctic, D23N Iowa. 
 
Fig.5 illustrates the location of these mutants, along with the correspondence to the 
APP sequence. Most mutations occur close to the -secretase cleavage site, increasing 
cellular production of A 40 and A 42, or just after the -secretase cleavage which 
selectively increases production of the more toxic A 42. 
 
A systematic investigation of the aggregation tendency of all 798 single-point 
mutations of A 42 was carried out using the Zyggregator algorithm (Section 4.5) to 
quantify aggregation propensity.
109g
 Seventeen mutants were then expressed in 
Drosophila melanogaster and properties including in vivo toxicity (survival time) and 
relative locomotor ability were correlated to the aggregation propensity. Mutants 
involving E22G (alone, or with one other residue substitution, except I31E/E22G) are 
found to be most highly pathogenic.
109g
 This is consistent with the observed higher 
rate of oligomerization and fibrillization of the arctic E22G variant compared to the 
wild-type peptide.
135
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2.3 Neuronal Toxicity of A  
 
At least for human neurons, intracellular A 42 is neurotoxic.
91b
  There is still some 
controversy about the precise location of A  aggregation in vivo,
1a
 although the 
endoplasmic reticulum and Golgi have been identified (see Fig.6).
41
 A review 
discusses the intra-cellular production of A .
41
 A novel super-resolution fluorescence 
imaging technique has been used to probe A 42 fibrillization within HeLa cells 
(differences in fibril morphology in vivo and in vitro were also noted).
136
 
 
A 42 is selectively intracellularly cytotoxic to human neurons, and not to other cell 
lines.
137
 A 42 but not A 40, A (42-1) or A (40-1) is toxic to human neurons.
137
 The 
proaptotic proteins Bax and p53 are implicated in this intracellular toxicity.
137-138
 
Disturbances in the cell division cycle may influence apoptosis in AD and this has 
been related to processing of APP and cyclin-dependent phosphorylation of tau.
138-139
  
 
Long-term potentiation (LTP) is a long-lasting enhancement of synaptic efficacy after 
brief high frequency stimulation. It has been widely used as a model of synaptic 
plasticity. A 42 and A 40 are known to disrupt LTP in neurons.
140
 Neurons from 
transgenic mice expressing genes encoding mutant APP
15,88,133,141
 or presenilin linked 
to FAD
1a,1b,55a,56
 exhibit damage to synapses and dendritic spine loss. A  is implicated 
in these defects because -secretase inhibition ameliorates some indicators of synapse 
damage.
141f,142
 Synthetic A 42 mediates long-term depression (LTD) in an NMDAR-
dependent manner in vivo 
143
 as does A  secreted by neurons that overexpress APP.
144
 
Deposition of amyloid plaques and deficits in LTP are observed together, although 
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spine loss and decrease in pre-synaptic terminal density is observed before plaque 
deposition probably pointing to the influence of oligomeric or pre-fibrillar A  on 
neurotoxicity. 
15,141d
 This is also supported by the fact that cognitive loss preceeds the 
observation of amyloid plaques.
88,141a-c,145
 Later work specifically implicated soluble 
oligomeric A  in synaptoxicity and inhibition of LTP.
140b,146
 (This is also discussed in 
section 2.6.1).  
 
Loss of glutamate receptors such as those for AMPA and NMDA caused by A  is 
implicated in synaptic depression and dendritic spine loss.
142,146d,147
 A  is known to 
inhibit LTP,
148
 as do A  fragments such as A (25-35).
149
 The blockage is mediated 
by stimulation of certain kinases.
150
 A -induced pathology may progress in a 
neurotransmitter-specific manner with different susceptibility for cholinergic, 
gluataminergic and GABAergic transmission (GABA = -amino butyric acid).
151
 
A (25-35) was used to investigate the effect of NMDA and GABA receptor 
antagonists.
152
 
 
A  binds to the 7 nicotinic acetylcholine receptor, nAChR, in neurons.
153
 This can 
result in receptor internalization and hence re-uptake of extracellular A .
41
 Since 7 
nAChR is co-localized with A  in plaques and A  disrupts calcium activation and 
acetylcholine release at the receptor, this interaction may be important in AD 
pathophysiology.
153a
 A  blocks the response of these nicotinic receptors, at least at 
high concentration
154
 (at low concentration A 42 seems to activate the 7 nAChR, 
although there is still controversy concerning this).
155
 Thus, stimulating nicotinic 
receptors (eg. with nicotine) protects neurons against A  toxicity.
154a,156
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Neuroprotection can also be achieved using 7-receptor agonists.
154a,155a
 However, 
long-term use of nicotinic agonists may induce desensitization of nicotinic 
receptors.
157
 This led to the proposed use of allosteric modulators which bind to a site 
on nAChR distinct from that of the natural acetylcholine binding site.
157
 The specific 
sequence A (12 28) was implicated in the inhibition of nicotinic currents.
158
 
 
GABA receptors are also potential targets to treat AD. Activation of GABA receptors 
increases neuronal vulnerability to toxic damage by A .
159
 This can be prevented by 
taurine (2-aminoethanesulfonic acid, related to tramiprosate, Fig.13) or GABA itself, 
or GABAA receptor agonists.
152,159
 
 
The role of microglia in the deposition of A  plaques (Fig.8) has been examined. 
Microglia are support cells involved in inflammation that surround senile plaques. 
Their role is not completely clear,
160
 since it has been proposed that they can clear 
amyloid deposits or alternatively may contribute towards their deposition (and 
particularly associated inflammation). Reactive microglia associated with A  plaques 
are involved in inflammation in AD. Fibrillar A  initiates a tyrosine kinase-based 
response in mouse microglia (and a human cell line) resulting in production of 
neurotoxic secretory species, proinflammatory cytokines and reactive oxygen 
species.
160b
 The cytokine TNF-  generated by monocytes and microglia is responsible 
for most of the A -induced neurotoxicity.
160b
 Cytokine TGF- 1 is also involved in the 
response to injury and has been found in the CNS of AD patients. It has been shown 
that TGF- 1 induceds A  deposition using a mouse model expressing this cytokine 
from astrocytes.
161
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Fig.8. Mechanism of plaque formation and associated migration of glial cells, based 
on work by Meyer-Luehmann et al.
162
 Reprinted by permission from Macmillan 
Publishers Ltd: Nature 451, 499, copyright 2008. 
 
Microinjection of fibrillar, but not soluble A , in the brains of aged rhesus monkeys 
leads to microglial proliferation as well as loss of neurons and tau phosphorylation.
160a
 
Fibrillar A  at plaque-equivalent concentration was found not to be toxic in the brain 
of young rhesus monkeys, pointing to the role of aging in promoting susceptibility 
towards A  neurotoxicity.
160a
 Microglia may enhance the toxicity of A  by releasing 
glutamate through the cysteine-glutamate transporter system xc
-
, and the neurotoxicity 
can be eliminated via inhibition of NMDA receptors or system xc
-
.
160c
 Microglial 
secretion of ApoE was found to exert a neuroprotective effect.
160c
  On the other hand, 
Nagele et al. investigated the role of microglia in A  plaque formation and found that 
they can facilitate the conversion of soluble and oligomeric A  into fibrillar form, and 
that microglia do not remove A  from plaques.
163
 These authors also highlight the 
role of astrocytes in accumulating A -positive material as part of their role in debris 
clearance in response to localized neurodegeneration. It is also suggested that A  
fibrillization can occur within the surface plasma membrane of microglia.
163
 In 
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contrast to the findings of Nagele et al., Simard et al. showed using a transgenic 
mouse model that bone-marrow derived cells (which can cross the BBB) that 
differentiate into microglia are able to eliminate amyloid deposits by cell-specific 
phagocytosis.
164
 Using multiphoton laser confocal microscopy, Meyer-Luehmann et 
al. showed that microglia are activated within 1-2 days of the appearance of a new 
plaque and that micro-plaques are rapidly formed that eventually develop into mature 
plaques (Fig.8).
160d
 Accumulation of microglia during inflammation can be mediated 
via Chemokine (C-C motif) receptor 2 (CCR2)-signaling and thus CCR2 and its main 
ligand CCL2 (MCP-1) might also be involved in the altered metabolism of Aβ 
underlying Alzheimer's disease (AD).
165
 Cannabinoids may also have a role in 
neuroprotection by blocking microglial activation.
166
 Senile plaques express 
cannabinoid receptors CB1 and CB2 together with markers of microglial activation 
and a synthetic cannabinoid was shown to prevent A -induced microglial 
activation.
166
 
 
The zinc metalloprotease insulin-degrading enzyme (IDE, insulysin) is central to the 
turnover of insulin and degrades A  in the mammalian brain.
108,167
 IDE forms a stable 
complex with A 40 and with A (17-27).
168
 IDE actually forms a complex with A  
monomer and not oligomers and so is not able to inhibit oligomer-induced loss of 
LTP.
146a
 Monomeric but not aggregated A  was able to associate irreversibly with 
IDE via the substrate binding site of the protease.
168
 The phosphorylation of A  at 
serine residue S8 reduces its clearance via IDE and angiotensin-converting enzyme 
(ACE).
169
 The other major endopeptidase involved in A  clearance is the zinc 
metalloprotease neprilysin (NEP),
170
 although other proteases capable of degrading 
A  have been investigated.
108b,167
 Aggregation-mediated A 42 toxicity is decreased 
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when aging is slowed (in a C. elegans model) by decreasing insulin growth factor-1-
like signaling (IIS), pointing to a link between the aging process and aggregation-
induced neurodegeneration
110c
 On the other hand, the transcription factors DAF-16 
and HSF-1 which express numerous chaperones (Section 3.2.2) regulate A  
aggregation and disaggregation activities respectively to promote cellular survival in 
response to toxic aggregation events (Fig. 9),
110c
 and may be the target for 
therapeutics. ACE plays an important role in blood pressure and body fluid regulation 
and sodium homeostatis. It is associated with AD in the Japanese population.
171
 ACE 
is found to inhibit A  aggregation and can degrade it by cleavage at N7-S8.
171b
 
 
Figure 9 shows schematically proposed pathways for in vivo aggregation of A 42, 
relevant to age-related proteotoxicity.
110c
 The IIS pathway is regulated by the receptor 
DAF-2 (inhibition of DAF-2 expression extends the lifespan of C. elegans worms). 
The transcription factors heat shock factor (HSF-1) and DAF-16 regulate opposing 
disaggregation and aggregation processes. The preferred mechanism whereby toxic 
aggregates are rapidly degraded (5-II) is positively regulated by HSF-1 (stage 5-A) 
and negatively regulated by DAF-2 (stage 5-C). When the HSF-1-regulated 
dissaggregation mechanism is overloaded, a second comes into play (5-III). This 
produces less toxic higher Mw aggregates. This is positively regulated by DAF-16 
(stage 5-B) and negatively by DAF-2 (stage 5-D). The high Mw aggregates can be 
eliminated by several methods indicated in the scheme. 
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Fig.9. Pathways of regulation of fibrillization in age-onset A  proteolysis.
110c
 
Adapted from Cohen, E. et al., Science 2006, 313, 1604. Courtesy of Ehud Cohen. 
 
2.4 Biomarkers for AD 
 
Biomarkers for AD are expected to improve the accuracy of diagnosis and to assist in 
differentiation of cases involving changes in A  metabolism. Biomarkers can also be 
used to investigate the influence of drugs on A  production (theranostics) along with 
safety monitoring, eg. of inflammatory responses in the case of adverse effects.
26
 A 
major public-private partnership initiative funded by the NIH, non-profit AD research 
organizations and major international pharma companies is the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI), which aims to identify biomarkers in volunteer 
patients.
172
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Different biomarkers may be appropriate during the progression of neurodegeneration 
towards AD leading to a dynamic model for applicable biomarkers as shown in Fig. 
10.
173
 
 
 
 
 
 
 
 
 
 
 
Fig.10. Dynamic events as a basis for use of biomarkers.
173
 A  is identified by CSF 
A 42 or PET amyloid imaging. Tau-mediated neuronal injury and dysfunction is 
identified by CSF tau among other indicators. Brain structure is probed using 
structural MRI. MCI = mild cognitive impairment. 
173
 Reprinted from Jack, C. R. et 
al., The Lancet Neurology, 2010, 9, 119. Copyright 2010, with permission from 
Elsevier. 
 
Research on biomarkers in CSF and plasma has recently been reviewed.
26,173-174
 The 
only established biomarkers are three that can be assayed in CSF: A 42, total tau (t-
tau) and p-tau (phosphorylated tau, at position threonine 181 or threonine 231).
19,175
 A 
combined analysis of two or more these biomarkers accurately diagnoses AD more 
accurately than a single one.
26
 The combination of these three analytes has high 
Amyloid
Tau-mediated neuron injury & dysfunction
Memory
Clinical function
Brain structure
Clinical disease stage
Normal
Abnormal
MCICognitively normal Dementia
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predictive value for prodromal (early symptomatic) AD.
26
 Reduced CSF A 42 (and 
A 40
176
) levels in cognitively normal elderly people who later developed AD have 
been observed from population-based studies
176-177
 and clinical studies.
178
 No changes 
were observed in CSF t-tau or p-tau.
176-177
 Biomarkers for tau phosphorylation appear 
specific to AD in contrast to changes in total tau and A 42 which are found in 
patients with other neurodegenerative diseases.
26
 An analysis of multiple study 
populations to examine potential CSF biomarkers for AD revealed that these three 
biomarkers can be used as diagnostics to predict incipient AD in patients with mild 
cognitive impairment.
19,175,179
 A total of eighteen signalling proteins have been 
identified in plasma that can predict for AD, the study being based on plasma samples 
from individuals with presymptomatic to late-stage Alzheimer’s disease and from 
controls.
180
 
 
Due to the need for invasive treatment (lumbar puncture) associated with 
measurements using CSF, reliable biomarkers in blood are also sought. It has been 
suggested that A (1-42) plasma levels are not a sensitive and specific indicator for 
early diagnosis.
26,174b
 This was ascribed to (i) the fact that plasma A  is derived from 
peripheral tissues and not the brain, (ii) variations in A  levels due to time-dependent 
fluctuations, (iii) binding of A  to other proteins, (iv) the influence of medications 
and (v) the involvement of APP and A 40 in platelet aggregation.
26,174b
 However, it 
has been reported that a reduction in plasma A 42/A 40 ratio is associated with 
cognitive decline over 9-10 years.
181
 Tau-related enzymes have been studied as 
potential blood biomarkers, including kinases involved in tau 
hyperphosphorylation.
174b
 However, it has been concluded that currently tau-related 
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biomarkers are not reliable diagnostics.
174b
 Several other potential blood biomarkers 
are discussed by Blennow et al.
26
  
 
Antibodies associated raised against A  (discussed further in Section 2.5) may be 
useful biomarkers.
172a
 A recent study reports the development of immunoglobulin G 
biomarkers for AD via a screening study using synthetic oligomeric peptoids to 
capture antibodies.
182
 
 
Biomarkers associated with inflammation have also been investigated, in particular 
proinflammatory cytokines.
174b
 Other disease-related biomarkers include ubiquitin 
and biomarkers related to cellular senescence such as p53 conformational state or 
telomere shortening.
174b
 Finally, there are biomarkers associated with cerebrovascular 
damage.
174b
 Other candidate CSF biomarkers include BACE, APP isoforms, truncated 
A  isoforms, A  oligomers, endogenous A  antibodies and neuronal and synaptic 
markers.
26,174a
 In particular, A  oligomers are promising biomarkers, however low 
CSF concentrations make sensitive detection a challenge.
174a
 Recently, the (small 
cytokine) chemokine (C-C motif) receptor 2 (CCR2) has been proposed as a CSF 
biomarker.
165
 
 
Methods to identify biomarkers for AD diagnosis based on different ELISA assays, 
mass spectrometry, DNA and gene chips etc are also discussed elsewhere.
174b
 
 
Imaging methods such as MRI (magnetic resonance imaging), fMRI (functional MRI) 
and PET (positron emission tomography) to diagnose AD are reviewed elsewhere.
173-
174
 The use of A  ligands for PET imaging has attracted attention, notably Pittsburgh 
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compound B (PIB, Fig.11b). This benzothiazole is derived from the well-known 
amyloid binding compound thioflavin T (Fig.11a) and it enables direct visualization 
of fibrillar A  load in the brain of living patients.
183
 Another widely used PET reagent 
is FDG, [
18
F]-2-deoxy-D-glucose, which is sensitive to neuronal glucose 
metabolism.
174a,183d
 Investigation of changes in the retina related to 
neurodegeneration, i.e. the monitoring of nerve cell death using in vivo cell marker 
methods, has been proposed as a method to screen for AD.
184
 Indeed, A  is deposited 
also in the retina. 
 
Fig.11. (a) Thioflavin T, (b) Pittsburgh-compound B (PIB) used as a tracer in PET 
imaging. 
 
The SERPIN (serine protease inhibitor) 1-antichymotrypsin has been shown 
to be a biomarker for Alzheimer’s, and is present in CSF.185 This is probably due to 
the role of oxidative stress and inflammation in Alzheimer’s, specifically in the 
overproduction of secretase,
118-119
 which in turn is correlated with A  load.
186
 
 
2.5. Antibodies to A  and Sequences Therein 
 
Table 3 lists antibodies raised against A  and A  sequences. These are widely used in 
studies to identify particular A  species produced in vivo. 
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Table3. Commonly used monoclonal A  antibodies. Developed from ref.
40
 
Name Epitope Ref. 
2G3 A (33-40) 
A (31-40) 
 
Specific for A 40 
161
 
187
 
188
 
3D6 A (1-5) 
161,187
 
4G8 A (17-24)  
A (17-28) 
87,189
 
24
 
6C6 A (1-16) 
106a,190
 
 
6E10 A (1-16) 
A (1-17) 
A (4-9) 
A (4-13) 
24,189c
 
189a
 
191
 
168,192
 
8F5  A 42 globulomers 
(docademeric 
oligomers) 
193
 
10D5 A (1-28) epitope 
A  (x-12) 
161
 
14C2 A (33-40) 
190b
 
14C12  A (13-28) 
190b
 
21F12  A (33-42) 
A 42 specific 
187
 
188b
 
266 A  “central 
domain” 
A (13-28) 
103,106a,188a,189b
 
 
106a,190a
 
 
Several polyclonal antibodies are also used, as listed for instance by Walsh et al.
40
 
 
An antibody, now known as A11, that recognises an epitope that is displayed 
specifically by soluble  oligomers of many polypeptides has been identified.
194
 The 
antibodies were raised in rabbits to an oligomeric model antigen comprising gold 
nanoparticles grafted with A 40. This antibody inhibits the toxicity of A 40 and 
A 42 oligomers.
194a
 This antibody also recognises oligomers from a range of other 
proteins and peptides.
194a
 Recognition was not observed for low Mw- or fibrillar- A  
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species. This indicates that the antibody recognises a common epitope in soluble 
oligomers. An antibody termed 8F5 is raised specifically against so-called A 42 
globulomers (docademeric oligomers).
193
 An antibody, distinct from A11, that 
recognizes on-pathway oligomers (i.e. pre-fibrillar oligomers) called OC has also 
been reported.
194b,194c
 An antibody against A (4-10) (FRHDSGY) inhibits A  
fibrillization and cytotoxicity, without generating an inflammatory response.
195
 
Similarly, an antibody against A (1-11) prevents aggregation of A 42 and causes 
disaggregation of preformed A 42 fibrils.
196
 The binding of fluorescently labeled 
antibody 6E10 to amyloid deposits within the TgCRND8 mouse brain has been 
observed, up to 2.5 mm away from the site of injection.
197
 
 
A number of monoclonal antibodies raised against oligomers and fibrils have been 
identified, which have activity against binding of A  to cells and reactive oxygen 
species generation.
198
 Antibodies that recognize the N or C terminal residues of A 42 
have been used in immunological studies using soluble dimers.
199
 A solution NMR 
structure of the complex formed between A 40 and an affibody protein ZA 3 indicates 
that this affinity ligand protein stabilizes the -sheet structure, and the hairpin 
observed in A 40 (section 4.1) is retained.
200
 Coexpression of ZA 3 with A 40 and 
A 42 can be used to produce both isoforms recombinantly.
201
 
 
2.6 Oligomers 
2.6.1 Toxicity of Oligomers 
 
It is now thought that oligomers formed in the initial self-assembly process of A  are 
the toxic agents.
2a,2d,6d,39,91,104,145a,194a,202
 Evidence for this comes from several 
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experiments on disease related and non-disease related proteins. In vivo and cell 
culture experiments showed that A 42 oligomers, formed under conditions that 
inhibited fibril formation, were neurotoxic.
91a,145a,202a
 Synthetic A  oligomers inhibit 
long term potentiation of neuronal cells, as discussed in more detail in section 2.3. It 
is possible to obtain naturally excreted SDS-stable oligomeric forms of A  and extract 
them from the conditioned medium of 7PA2 Chinese Hamster Ovary 
cells.
40,105,146a,146d,189b
 The oligomers are produced soon after generation of human A  
in intracellular vesicles in CHO cells which express an APP isoform. The intercellular 
production of oligomers, principally dimers, was inferred from previous studies using 
primary human neurons.
40
 The secreted oligomers (predominantly dimers and trimers 
in the conditioned medium, i.e. released from the microsomes) disrupt the LTP of rat 
hippocampal neurons
146a,146c,146d
 as discussed further in section 2.3. These oligomeric 
forms of A  were also shown to disrupt the learning behaviour of rats.
104
 The soluble 
oligomers induce tau hyperphosphorylation leading to disruption of the microtubule 
skeleton and neuritic degeneration.
199
 
 
Further evidence in support of the toxic oligomer hypothesis comes from the 
observation that molecules that stabilize fibrils by accelerating A  fibril formation 
leads to a loss of inhibition of LTP by A  oligomers.
191
 An orcein-related small 
molecule O4 was found to bind to hydrophobic residues in A  and to promote the 
formation of -sheet rich fibrils whilst decreasing the concentration of oligomers.
191
 
 
Anti-A  antibodies isolated from immunoglobulin strongly disrupt fibrillization.
203
 
Experiments using polyclonal antibodies indicate that they suppress the toxicity of 
soluble oligomers whereas there is no antibody response to mature fibrils.
194a
 This has 
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been proposed as a route to vaccination using A 42 oligomers.
204
 Experiments on A , 
-synuclin and transthyretin suggest that cytoxicity shares a common cause not 
related to the specific sequence.
39a,39c
 Recent in vivo studies using a mouse model 
suggest that specific soluble A  multimeric species are associated with memory loss 
in Alzheimers, specifically dodacameric 56 kDa species.
87
 
 
Inhibition of -secretase can prevent oligomer formation and restore LTP of rat 
neurons.
146a
 Two -secretase inhibitors (flurbiprofen and semagacestat, Fig.13) 
recently reached, but failed, phase 3 trials. Possible reasons for the failure of these 
trials that do not necessarily invalidate the A  hypothesis have been discussed.
3,49
 The 
-secretase inhibitor semagacestat developed by Eli Lilly
205
 also failed phase 3 trials 
due to low potency and signs of apparent Notch toxicity including gastrointestinal 
symptoms and skin cancer.
3,49
 
 
A  oligomers adversely affect synapse function.
140b,206
 This leads to the damage to 
neuropili believed to underlie AD.
206
 A  oligomers may inhibit long-term potentiation 
and facilitate long-term depression,
147b
 depending on the extent of change in the 
calcium ion concentration, although there is still controversy around this issue. This 
has been associated with the synaptic removal of AMPA receptors (AMPARs).
140b
 
Soluble oligomers, whether naturally secreted or prepared from synthetic A , inhibit 
hippocampal long-term potentiation,
146a,207
 due to removal of AMPA receptors
140b
 and 
disruption of neuronal glutamate uptake.
147b
 They also cause a rapid decrease in 
membrane expression of memory-related receptors such as NMDA and EphB2.
206
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The importance of “gatekeeper residues” that cap aggregation prone sequences in 
natural proteins and help to hinder aggregation into fibrils has been highlighted.
202c
 
There is clearly scope for evolutionary pressure to ensure that proteins contain 
residues that hinder aggregation and/or promote folding into the native state.
202c,208
 
Specific residues that oppose aggregation were analysed using a computer algorithm 
that analyses sequence aggregation propensity, including those in A  as discussed 
further in Section 4.5.
202c
 
 
Several characteristics of the AD phenotype can only be replicated using oligomers, 
including synaptic loss, hippocampal synaptic plasticity, microgliosis and tau 
hyperphosphorylation.
3,49
 The presence of oligomers trapped within plaques, points to 
the dynamic equilibrium that may exist between these species. Oligomers are formed 
intracellularly in human neurons.
40
 They appear mainly in the form of dimers.
40
 
Oligomers influence synaptic plasticity and impair LTP in brain tissue.
6e,140b,146,188b
 
The molecular conformation of a highly synaptotoxic A  oligomer structure has 
recently been eludicated using ssNMR.
209
 This study revealed that the oligomer 
formation is controlled by an N-terminal -strand. 
 
Stable SDS-resistant oligomers have been detected in normal and AD brain.
210
 
Oligomers comprising dimers and trimers were detected in tissue extracted from AD 
brain,
210b
 and AFM revealed that these structures comprise 3-4 nm diameter 
ellipsoids. A -Derived Diffusible Ligands (ADDLs) formed by A 42 have been 
imaged by liquid state AFM.
211
 AFM has also been used to compare the formation of 
oligomer-like species and protofibrils by A 40 and A 42.
212
 AFM has also been used 
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to image the oligomer-induced formation of membrane pores, as discussed further in 
section 2.7. 
 
2.6.2 Types of Oligomers 
Various types of oligomeric species have been identified, such as protofibrils, 
paranuclei, globulomers or so-called A -Derived Diffusible Ligands (ADDLs),
146d
 
especially in the early literature which is not reviewed in detail here. Distinctions 
between these species have been summarized.
1c,6e,213
 ADDLs are larger (4-6 nm 
diameter) structures than “low n” (where n is the number of associated monomers) 
oligomers or globulomers.
213
 ADDLs are thought to comprise mixtures of monomer 
and heterogeneous higher n oligomers.
1c
 The observation of these oligomeric 
structures depends on how synthetic A  is prepared and incubated. More recently, as 
discussed below, protocols to prepare oligomers from synthetic A  in a controlled and 
reproducible manner, or in the secreted medium of a rodent cell line (7PA2), have 
been described.
146d
 The natural A  oligomers are resistant to SDS and insulin-
degrading enzyme (IDE) which can only digest monomeric A .
6e
 All soluble 
oligomers display a common structure against antibodies raised against them (A11 
antibody, section 2.5).
194a
  
 
Stable globular oligomers termed globulomers can be prepared by careful preparation 
methods starting from A  monomers. Different groups report various protocols to 
prepare stable oligomers.
193,214
 Using synthetic A , Kayed and coworkers prepare 
oligomers by controlled evaporation of HFIP which is used to disperse A  into 
monomeric form
194a,215
 followed by redispersion in water, or dissolving the peptide in 
NaOH and diluting this stock solution in a PBS solution containing sodium 
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azide.
215b,216
 Chromy et al. reported a related method to prepare stable oligomers from 
synthetic peptides.
214
 As mentioned in Section 2.6.1, the 7PA2 CHO cell line 
expressing mutant V717F APP has been developed to secrete A  in oligomeric 
form.
189b,213
 The oligomers produced by Chromy et al. are neurotoxic
214
 and block 
LTP.
193
 Electrophoresis in denaturing gels revealed a spectrum of oligomers including 
dimers, trimers, tetramers, pentamers, and higher order oligomers up to 24-mers.
217
  
 
Globulomers can be prepared by incubation in the presence of SDS or fatty acids. 
193,218
 These oligomers appear to be dodecameric species with a mass of 60 kDa. They 
raise oligomer-specific antibodies 8F5 (cf. Section 2.5).
193
 They could be related to 
the brain-derived soluble A
*
56 dodecamers.
6e,207
 Solution NMR has been used to 
characterize A (M1-42) globulomers indicating a mixed parallel and antiparallel 
configuration 
219
 and a dimeric state. To confirm that the globulomers (oligomers) 
comprise repeats of the dimer, a mutant peptide with L17C, L34C substitution to 
enable disulfide crosslinking was prepared. This was found to bind to anti-oligomer 
antibodies with the same affinity as the WT peptide.
219
 The mixed -sheet 
configuration is in contrast to fibrils which contain only parallel -sheets (Section 
4.1). A  oligomers can be used to cross-seed tau oligomers.
215b
  
 
Electrospray mass spectrometry has been used to probe oligomeric states, in particular 
via analysis of arrival time distributions which can distinguish distinct species with 
the same charge/mass ratio due to differences in cross-sections of the ions 
generated.
217
 This technique reveals that unfiltered solutions of A 42 contain 
monomers and large oligomers.
217
 Filtration can be used to isolate smaller oligomers 
– dimers up to dodecamers, the latter being proposed as the species that initiate 
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fibrillization.
217
 Later, the same ion mobility mass spectrometry method was applied 
to investigate oligomer formation by A 42 with a comparative study to A 40.
220
 For 
A 42, oligomers up to dodecamers were observed whereas for A 40 only oligomers 
up to tetramers were found. The authors proposed different mechanisms of fibril 
nucleation based on these observations (Fig.12).
220
 These distinct aggregation 
mechanisms were supported by earlier conclusions from experiments using photo-
induced cross-linking of unmodified proteins (PICUP)
221
 to cross-link oligomers 
which were analysed using a variety of sizing techniques.
221a
 These studies showed 
that the formation of monomers up to tetramers only are observed for A 40, whereas 
pentamer/hexamer paranuclei are formed preferentially by A 42. 
 
 
Fig.12. Distinct mechanisms of aggregation of A 42 and A 40 proposed by 
Bernstein et al.
220
 M denotes monomer, D dimer, Te tetramer and the initial toxic 
species for A 42 is proposed to be the dodecamer whilst the planar hexamer serves as 
a paranucleus. Reprinted by permission from Macmillan Publishers Ltd: Nature 
Chemistry 1, 326, copyright 2009. 
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Single molecule fluorescence methods indicate that in vitro A 40 forms a 
heterogeneous distribution of small oligomers (from dimers to 50-mers).
222
 The 
oligomers represent about 1% of the total number of species present, at the 
concentrations examined (30 nM to 2 M). Oligomers have been shown, by SAXS, 
SDS-page and Western blotting, to bind to APP.
223
 Dimers of A  cause APP to 
dissociate from the native homodomer conformation into monomers, whereas A  
oligomers bind to APP but its homodimer structure is preserved.
223
 
 
2.7 Ion Channel Hypothesis 
 
The mechanism of A  cytotoxicity may be due to its ability to form membrane pores 
or channels.
2d,58a,224
 This could be due to the exposure of hydrophobic regions in 
misfolded proteins such as those that form amyloid fibrils.
224b
 Positive charge on a 
peptide that enables interaction with negatively charged lipid membranes may also be 
important.
224b
 According to the channel hypothesis, pore formation is responsible for 
the neurotoxicity of A . The original work by the group of Arispe et al.
225
 established 
that A  is capable of forming membrane channels.  
 
The oligomeric form of A  is implicated in pore formation.
224g,226
 Lambert et al. 
showed that A 42 oligomers bind to cell membranes and cause cytotoxicity under 
conditions in which mature fibrils do not form.
202a
 Further support for this is the 
finding that pore formation is inhibited by Congo red binding,
227
 indicating that the 
A  needs to be aggregated into protofilaments/oligomers for this mechanism to be 
effective. A  forms pores in lipid membranes that contain multimers of the protein, as 
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revealed by AFM.
226a
 Evidence for pore formation in vivo has also been obtained via 
TEM on neuronal cell membranes.
228
 
 
Uptake of Ca
2+
 across the ion channels leads to neuronal degeneration in a dose- and 
time- dependent manner and ultimately cell death.
226a
 Changes in the calcium level 
and the morphology of cultured cells was also found to be sensitive to the aggregation 
state of A 42.
229
 A  pore formation leading to an increase in intracellular calcium has 
been linked to depletion of synaptic vesicles and hence blocked neurotransmission.
230
 
Transient Ca
2+
 currents are observed near A  plaques in the brain of transgenic mice 
suggesting the presence of clusters of “hyperactive” neurons.231 A correlation between 
an increase in calcium ion production and a decrease in A  production has also been 
noted in studies on SERCA (sarco ER Ca
2+
 ATPase) which is a calcium channel-
forming protein in the endoplasmic reticulum (ER) membrane.
232
 Down-regulation of 
SERCA leads to increased Ca
2+
 and reduced A  levels and over-expression leads to 
increased A  production. SERCA activity was also shown to be decreased in 
fibroblasts lacking the PS1 and PS2 presenilin genes.
232
 
 
2.8 Interaction of A  with tau 
The tau protein is involved in microtubule assembly and stabilization within the 
cytoskeleton (in particular in F-actin fibrils). Mutations can lead to filamentous 
deposits which have been observed for several neurodegenerative diseases such as 
Pick’s disease, Parkinsonism-dementia complex of Guam etc.2a Filamentous tau 
deposits are invariably present even in the absence of A  deposits and it is not clear in 
the context of fibril deposition precisely how A  and tau interact although there 
seems to be a synergistic effect which enhances actin bundling and 
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neurodegeneration.
2a
 Neuronal degeneration induced by tau has been studied in vivo, 
although this is outside the scope of the current review. However, tau can influence 
A -induced neuronal dysfunction, as exemplified by a study using transgenic mice 
that express APP along with tau.
4a
 Synergistic interactions between A , tau and -
synclein can accelerate neuropathology and cognitive decline, as indicated by a study 
using transgenic mice.
233
 These authors note that the aggregation of -synuclein into 
Lewy bodies is a pathology associated with up to 50% of AD cases. 
 
A correlation between an increase in CSF tau and ptau-181 and the amount of cortical 
amyloid has been reported via brain imaging studies using the PIB biomarker (Section 
2.4).
234
 There is an inverse relationship involving cortical PIB binding, i.e. A 42 
deposition is inversely related to CSF A 42 levels, but this is not true for plasma 
species.
183c,234
 
 
3. THERAPEUTIC TREATMENTS 
3.1 Existing treatments 
The only drugs currently available do not cure AD but may delay the development of 
symptoms. The current standard of care for mild to moderate AD includes treatment 
with acetylcholinesterase inhibitors to improve cognitive function and memantine, an 
NMDA antagonist. The acetylcholinesterase inhibitors include galantamine, an 
alkaloid available commercially as Reminyl (Shire), Razadyne (Janssen), rivastigmine 
(Exelon, Novartis) and donepezil (Aricept, Pfizer).
8,31,235
 The patent on the latter drug 
expired in 2010,
236
 however it has recently been shown that it may also be effective in 
the treatment of moderate-to-severe AD as well as mild-to-moderate symptoms.
237
 
The cholinesterase inhibitor tacrine is rarely used due to poor oral bioavailability and 
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several potential adverse drug reactions.
31
 The NMDA receptor antagonist memantine 
developed by Eli Lilly is also available under trade names including Ebixa 
(Lundbeck) and Namenda (Forest).
8,31
 The development of the market for these drugs 
(sales forecasts) has been assessed – sales were $4 billion in 2005.8 
 
Although developed as an acetylcholinesterase inhibitor, galantamine also acts to 
inhibit A  aggregation.
238
 It is also known as an allosteric modulator of nicotinic 
receptors.
239
 Memantine is thought to function therapeutically as an open-channel 
blocker of NMDA receptors,
240
 and also attenuates the ADDL-induced increase in 
intraneuronal calcium.
241
 
 
3.2 Inhibitors of Fibrillization/Oligomerization 
3.2.1 Small Molecules 
Since there have been a very large number of papers on small molecule inhibitors of 
A  fibrillization (also -secretase inhibitors) we are not able to review all of them. 
Reviews on this topic are also available.
242
 Here, we focus on key classes of 
compounds and individual compounds that have attracted particular interest, for 
example moving to advanced stage clinical trials. Other reviews cover many more of 
the compounds researched to date. The main focus in the following is on A  
fibrillization inhibitors, as this has been the main focus of small molecule inhibitor 
approaches.
189c,216,242a,242b,242d
 However, some compounds have been developed to 
inhibit -secretase or -secretase.
242a
 
A large number of small molecules have been studied for their ability to influence A  
aggregation and toxicity.
216,242
 Possibly the most high profile work has been on 
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tramiprosate (Alzhemed, 3-amino-1-propanesulfonic acid, Fig.13) which reached 
phase III trails, which however were not successful.
3,49
 This compound is a 
glycosaminoglycan (GAG) mimetic (vide infra) shown to bind to soluble A 40 and 
A 42 and to maintain them in a non-fibrillar form.
242d,243
 It also decreases A 42-
induced neurotoxicity, is able to cross the blood-brain barrier (BBB) and, using a 
TgCRND8 mouse model, can reduce amyloid plaque and cerebral levels of A 40 and 
A 42.
243a,244
  
 
 
 
Fig.13. Therapeutic compounds for AD.  
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A number of dye compounds have been investigated in terms of their effect on A  
aggregation and neurotoxicity.
196
  Congo red (CR), an amyloid-staining dye, has been 
the subject of several studies in this regard.
245
 CR is found to inhibit fibril formation 
and neurotoxicity towards rat hippocampal cells.
245b
 NMR and light scattering suggest 
that it binds to A 40 monomers
245e
 and AFM indicates that this ultimately leads to a 
distinct aggregation pathway.
245f
 However, CR is potentially toxic due to the 
metabolic release of benzidine, and has poor BBB permeability.
245d
 CR has been 
found by Podlisny et al. to inhibibit the oligomerisation of A 40 using the A  
expressed by 7PA2 cells in conditioned medium (see Section 2.6.1).
105,189b
 In contrast, 
Knowles and Dobson et al. found CR has no effect on A  fibrillization.
246
 It has been 
suggested that CR binding arises from a specific conformation of the sulfonate groups 
in the compound which bind A  via electrostatic interactions.
242d
 Other sulfonated 
dyes investigated as A  aggregation inhibitors include chrysamine G and thioflavin 
S.
242d
  Methylene blue inhibits A  oligomerization by stimulating fibrillization.
247
 It 
has low toxicity and is able to cross the BBB. Wong and coworkers have studied a 
series of Brilliant blue derivatives, which are food dyes with blood-brain barrier 
permeability properties.
189c
 Reduction in A -induced cytotoxicity due to the 
formation of off-pathway non-toxic aggregates was noted for some derivatives.  
 
Necula and coworkers investigated a large series of compounds including many dye 
molecules and classified them according to whether they selectively inhibit the 
fibrillization or oligomerization of A 42, or both.
216
 The existence of these different 
classes of inhibitors might suggest that the pathways of A  oligomerization and 
fibrillization are independent. However, as discussed in section 2.6, whether 
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oligomers are on- or off-pathway intermediates is still an open question.
248
 In a 
similar analysis of a smaller number of aromatic compounds, including dyes and 
polyphenols, Ladiwala et al.
249
 classified the molecules according to whether they (i) 
remodel soluble oligomers into large non-toxic off-pathway aggregates (some also 
remodel fibrils), (ii) convert soluble A  oligomers into fibrils but are inactive against 
fibrillar A  or (iii) disaggregate soluble oligomers or fibrils into non-toxic low-
molecular weight species (Fig.14). 
 
 
Fig.14. Pathways of aggregation for different classes of small molecule inhibitors of 
A  oligomerization/fibrillization.
249
 This research was originally published in 
Ladiwala, A.R.A. et al., Journal of Biological Chemistry 2011, 286, 3209. © The 
American Society for Biochemistry and Molecular Biology. 
 
Polyphenols are also able to influence A  aggregation. A review provides details of 
the many compounds investigated in this context
250
 and another review describes the 
associated mechanisms of action with a focus on the antioxidant role of these 
compounds.
251
 Polyphenols that have attracted particular attention such as tannic acid 
and epigallocatechin gallate (EGCG) have been shown to reduce A  cytotoxicity in 
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cell-based assays,
242a,242d,249,252
 and can disassemble mature A 42 fibrils
252b
 although 
these compounds are not able to cross the BBB.
189c
 Catechins and related polyphenols 
have also been shown to inhibit A  fibrillization, as assayed using ThT 
fluorescence.
242a,253
 It has been noted that competitive binding of the analyte and ThT 
means that these results need to be treated with caution.
254
 Other biologically derived 
polyphenols including NDGA (nordihydroguaiaretic acid), curcumin and rosmaric 
acid have also been examined as A  aggregation inhibitors, or in terms of 
disaggregation of pre-formed fibrils.
242a,242d
 Research has developed to the stage of in 
vivo studies using Tg2576 mice, with a focus on the pathway of A  aggregation, i.e. 
via oligomers or otherwise.
255
 Curcumin can cross the BBB and has been shown to 
reduce plaque burden using a Tg2576 mouse model.
256
 Resveratrol, a polyphenol with 
antioxidant properties found in wine has been shown to inhibit A 42 fibril formation 
and to reduce cytotoxicity.
257
 
 
Gazit and coworkers have screened a series of small molecule inhibitors of A  
aggregation that contain aromatic recognition elements as well as -breaker units.
258
 
A lead compound NH2-D-Trp-Aib-OH was identified. This compound is able to 
inhibit the formation of toxic oligomers and in vivo studies using a model mouse 
(expressing human APP Swedish and London mutations) also indicated improved 
cognitive function.
258
 
 
Metal ion chelators, in particular of Cu
2+
 and Zn
2+
, have also been shown to inhibit or 
reverse aggregation of A  in vitro.
242a,242d,259
 Cherny et al. indicate that to efficiently 
extract A  from brain tissue using metal ion chelators including EGTA and ethylene 
diamine, Ca
2+
 or Mg
2+
 are also required.
259a
 Metal ion chelators can be specific to 
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particular ions, for example clioquinol (Fig.13a), an anti-malerial quinone, selectively 
binds Zn
2+
 and Cu
2+
 with greater affinity than Ca
2+
 and Mg
2+
  and reduces brain A  
deposition in an Tg2576 mouse model.
260
 Studying A 40, Raman et al. found that 
Zn
2+
 and Cu
2+
 but not Fe
3+
 reduce fibril formation, however pre-formed fibrils are 
stable in the presence of these metal ions. Clioquinol-induced resumption of fibril 
growth suppressed by Cu
2+
 but not Zn
2+
, points both to a chelation effect but also a 
synergistic effect of a Zn
2+
-clioquinol complex on A 40 fibrillization.
259b
 A successor 
to clioquinol is the 8-hydroxyquinoline analogue PBT2 which reached phase II 
clinical trials, and shows ability to reduced CSF A 42 levels as well as cognitive 
performance.
261
 This compound is believed to perform as a superior ionophore than 
clioquinol, i.e. to more effectively promote the transport of copper and zinc ions 
across cell membranes.
261b
 It is also designed to be easier to synthesize, more soluble 
and to have increased BBB permeability.
261b
 The role of metal ions in the inhibition of 
A  fibrillization or promotion is discussed further in Section 4.8. Inspired by 
clioquinol, bifunctional compounds that can interact with both metal ions and A  
have been developed based on pyridine/stilbene derivatives
262
 and related 
pyridinones.
263
 These compounds can disaggregate A 40. A responsive copper 
chelator that is released when a pro-chelator is cleaved by -secretase has been 
developed and shown to inhibit Cu
2+
-induced A  aggregation.
264
 Similarly, a pro-drug 
compound comprising a glycosylated (glucose-receptor targeting) metal ion chelator 
(hydroxypridinone) is able to cross the BBB with enzymatic loss of the glucose 
unit.
265
 The compound has an antioxidant property. 
 
Compounds that can block A -induced channel formation in lipid membranes 
including tromethamine have been investigated via conductance 
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experiments.
225a,225b,266
 Zinc can also block such channels.
229,266b
 Arispe et al. also 
developed a peptide-based channel blocker, designed specifically to modulate late A  
effects on caspase activation and apoptosis.
266b
 
 
Glycosaminoglycans or proteoglycans have been associated with AD since sulfated 
GAGs such as heparan or chondroitin sulfate are present in neuritic plaques, 
neurofibrillary tangles and vascular amyloid deposits.
242d,267
 Binding of some sulfated 
GAGs can prevent the proteolytic degradation of fibrillar A . Heparan or heparan 
sulfate can accelerate the fibrillization of A  in vitro,
267b
 probably due to electrostatic 
binding to a specific domain in the A (11-28) region.
245a
 Chondroitin sulfate also 
promotes the aggregation of A 2 into stable fibrils of reduced toxicity.
268
 These 
studies suggested that inhibitors of this interaction might prove useful as therapeutic 
agents.
242a
 In a related manner, sulfated compounds such as heparin and dextran 
sulfate can inhibit the interaction of heparan sulfate with A .
269
 Some sulfated 
compounds inhibit A  aggregation. Synthetic glycopolymers bearing sulfated 
saccharide units are also able to suppress the fibrillization of A 42, A 40 and A (25-
35).
270
 Simple sugars can either accelerate or inhibit fibrillization.
271
 As mentioned 
above, the GAG-mimetic tramiprosate (Fig.13b) reached phase III clinical trials but 
was not successful despite reducing CSF A 42 levels in mild-to-moderate AD 
patients.
243b
 Reviews that discuss the effect of GAGs on A  aggregation are 
available
267b,267c,272
 (the former considers also proteins and lipids). The location and 
distribution of sulfate groups on the GAG chains may define the interaction with 
A .
267c,273
 Fibril formation of A 42 is actually promoted in the presence of GAGs 
with a suitable spacing of sulfate units, although the cationic polysaccharide chitosan 
can inhibit such aggregation.
273
 Fraser and coworkers showed that in the presence of 
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low concentrations of sulfate ions, A (11-28), A (13-28), and A (11-25), but not 
A (15-28) undergo extensive lateral aggregation into “macrofibers”.245a  Ariga et al. 
point to the key role of the A (13-16) HHQK region in the binding process, 
especially the histidine residues.
274
 They also note that low molecular-weight heparins 
can inhibit fibril formation. 
 
As discussed in the Introduction, oxidative stress plays an important role in AD.
17
 The 
role of antioxidants as novel neuroprotective agents has been reviewed, including 
polyphenols and other nutraceuticals such as flavonoids and turmeric.
235,251
 The 
effects of a series of flavonoids, catechins and related compounds on A 42 
fibrillization has been compared and cytotoxicity studies were performed on fibril 
inhibitors (some fibril promotors were also identified) leading to the identification of 
promising lead compounds.
275
 The structural features of derivatives of the flavonoid 
fisetin involved in A 42 fibril inhibition have been probed.
274
 Several studies have 
suggested that antioxidant vitamins may reduce neurotoxicity, due to their role in 
alleviating oxidative stress.
242a
 
 
Lipid-based small molecule inhibitors have also been developed, since the presence of 
lipid membranes may accelerate A  fibrillization,
267c
 since A  deposition is initiated 
in a plasma membrane-bound form (Section 4.7). A particular focus has been on the 
interaction of A  with phosphatidylinositol since this causes a dramatic increase in 
fibril growth.  This can be inhibited using headgroups from other members of the 
phosphatidylinositol family.
276
 This led to the identification of scyllo-inositol (cyclo-
hexanehexol, Fig.13c) as lead compound.
277
 This compound stabilizes an oligomeric 
form of A .
277
 Administration to TgCRND8 mice prevented A  plaque formation, 
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synaptic toxicity and cognitive deficits.
84b
 These effects were seen both in 
prophylactic and treatment studies.
278
 The compound has high availability due to the 
presence of the inositol transporters at the BBB. This compound has reached phase II 
trials (as AZD-103, Transition Therapeutics).
279
 
 
The action of other compounds on A  aggregation including nicotine, melatonin, 
rifampicin and tetracyclines has been reviewed.
242a
 
 
Inhibition of A  aggregation has been targeted via use of self-recognition elements 
(SREs). These are molecules based on fragments of the A  peptide, which are capable 
of binding to the corresponding sequence in the native peptide, but are modified so as 
to disrupt -sheet fibrillization.
242d
 Findeis et al. proved that compounds based on a 
core sequence of the A  peptide implicated in fibrillization, A (16-20) (KLVFF), 
showed promise as SREs.
280
 Murphy and co-workers have investigated the effect on 
A  aggregation of compounds based on KLVFF extended at the C-terminus by 
cationic or anionic residues to give, for example, KLVFFKKKKKK or 
KLVFFEEEE.
281
 Molecules containing three or more lysines in the extension were 
found to be most effective.
281-282
 Modified versions of these compounds have been 
used to examine the role of surface tension on the kinetics of aggregation of A 40.
283
 
The compounds contained modifications including charge, branching, D/L-isomer 
substitution and counterion type (motivated by the Hofmeister series) that influence 
the stabilisation of the protein structure. Gordon and co-workers studied the N-
methylated compound A (16-20)m and showed that it inhibits fibrillization of A (1-
40).
284
 N-methylation of alternate residues disrupts -sheet self-assembly due to the 
presentation on one face of the -strand of residues incapable of adopting the usual 
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hydrogen bonding pattern.
284
 Doig and co-workers have followed this up and screened 
a number of N-methylated “meptides” based originally on the same sequence, but 
with all D-amino acids and with modifications of the termini and incorporation of 
branched residues in certain positions, that are promising as SREs towards targeted 
aggregation inhibitors, and which also contain elements to improve their 
pharmacokinetics.
242c,285
 A lead compound based on a pentapeptide framework has 
been shown to have favourable cytotoxicity, and to reverse the inhibition of  LTP by 
A 40.
242c
 Doig et al. have also reviewed other promising compounds.
242b,242c
 Austen 
et al. have developed compounds based on KLVFF but with terminal modifications to 
aid solubility and showed that these were effective inhibitors of toxicity using human 
neuroblastoma cells.
286
 The binding of -alanine and GABA-modified peptide 
fragments to amyloid fibrils formed by -synuclein, A 40 and amylin has recently 
been examined.
287
 The binding sequence was based on self-recognition element 
V
77
AQKTV
82
 of the full length -synuclein peptide and shorter sequences therefrom. 
Pentapeptides containing gamma-amino acids and the KLVFF SRE (or its D-amino 
acid variant) have also been examined, and a promising compound able to reduce A  
toxicity, due to inhibition of fibrillization, was identified.
288
 Watanabe and coworkers 
have shown by a binding assay using immobilized KLVFF in the presence of 
fluorescently-labelled KLVFF in solution that the KLVFF motif is a self-recognition 
element.
289
 Incorporation of the retro-inverse peptide ffvlk into cross-linked PEG 
networks (as a monomer, dimer or tetramer, all linked to PEG via a cysteine residue) 
produces gels that can bind A 42.
290
 It was proposed that these gels could serve as 
sinks or “detoxification depots” to capture A . 
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Ligands that stabilize the A (13-26) domain in an -helical conformation (as revealed 
by NMR, section 4.1)  have been studied as a means to reduce aggregation of A 40 
and A 42, and also cytotoxicity.
109e
 The inhibitors were based on self-recognition 
modelling of the A (13-23) region and comprise two peptidomimics and N-decanoyl-
diethyelenetriamine. Studies using a Drosophila melanogaster model (expressing 
human A 42) also suggested reduced neurodegeneration in the presence of the 
molecules.
109e
 Schrader and coworkers have explored the use of functionalized 
aminopyrazole derivatives in binding to A 42.
291
 Ligands bearing multiple lysine 
residues were found to interact with the ladder of stacked E22 residues and to 
completely dissolve pre-existing fibrils.
291b
 These ligands interact through 
electrostatic and hydrophobic interactions with the KLVFF sequence although 
lipophilic groups on some of the designed ligands can interact with the nonpolar 
residues between I31 and V36.
291
 This group have also developed lysine-specific 
molecular tweezers (Fig.15) with aromatic pincers able to inhibit the aggregation and 
toxicity of A 40 and A 42.
292
 Mihara et al. have shown that even dipeptides LF and 
CF can form mixed fibrils with small amounts of A 42, hence “capturing” the 
peptide.
293
 
 
 
Fig.15. Lysine-specific molecular tweezers CLR01 and CLR03. Reprinted with 
permission from ref.
292
. Copyright 2011 American Chemical Society. 
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Statins reduce cholesterol levels in blood and this in turn correlates to A  production 
and aggregation as discussed in Section 4.7. Reduction in cholesterol using lovastatin 
and methyl- -cyclodextrin inhibits the production of A  in hippocampal neurons 
without altering APP production.
294
 
 
In a novel approach related to the “toxic oligomer” hypothesis (Section 2.6.1), the 
action of selective fibrillization accelerators (with an oligomer-reduction activity) has 
been probed.
191
 Compounds related to the dye orcein are shown to accelerate A 42 
fibril growth, while reducing oligomer formation. 
 
3.2.2 Proteins and Particles 
 
Chaperone proteins have been shown to bind to A  and to inhibit fibrillization/ 
oligomerisation. Several proteins that interact with intracellular A  in vivo have been 
identified based on mass spectrometry analysis of human A  expressed in C. elegans. 
including the small heat-shock protein B-crystallin and related proteins such as 
members of the HSP70 family.
295
 B-crystallin is a chaperone for A , binding to it, 
and preventing fibril growth.
296
 It prevents the spontaneous fibrillization of A 42
296
 
and the A 42-seeded growth of A 40.
296a
  The extracellular chaperone protein 
clusterin has been shown to sequester oligomers of A 40  during aggregation and 
disaggregation.
101
 As discussed above, clusterin (apolipoprotein J) is an identified risk 
factor in Alzheimer’s disease.54,64 A large-scale screening study has recently 
identified small molecule proteostasis regulators that induce expression of the 
chaperone heat shock transcription factor-1 (HSF-1).
297
 This may form the basis to 
 67 
treat a number of protein conformational diseases including AD. The inhibition of 
fibrillization in the presence of clusterin (Section 2.1.1) has also been examined.
298
  
 
Other proteins and peptides have been shown to bind A  and to influence its 
aggregation. The secretory protein gelsolin
299
 and the ganglioside GM1
300
 are able to 
bind A , and it has been proposed that peripheral treatment with these materials can 
be used to reduce A  levels in brain (mouse model).
301
 Transthyretin, itself an 
amyloidogenic protein, and variants, can inhibit the aggregation of A  in vitro and in 
vivo.
302
 The cellular prion protein PrP
C
 is also able to bind A  oligomers at nanomolar 
affinity, indicating that it may act as a receptor and that it is involved in A -induced 
synaptic disfunction in the mouse brain.
303
 However, these findings have not been 
replicated by two other groups who found that mice suffered memory deficits even in 
the absence of prion protein, carefully excluding PrP
C
.
146e,146f
 Very recent work 
suggests that cellular PrP
C
 is essential for oligomeric A -induced cell death, since 
PrPC antibody blocks A  oligomer-induced neurotoxicity and mice expressing PrPC 
are resistant to A  toxicity.
304
 It has been proposed that PrP
C
 may have a 
physiological role in modulating NMPAR activity, mediated by copper ions, which is 
disrupted in the presence of A 42 (section 4.8).
305
 
 
Polymeric nanoparticles (uncharged acrylamide-based copolymers) inhibit the 
fibrillization of A 40, an observation ascribed to the binding of A  (in monomeric or 
oligomeric form) to the nanoparticles.
114
 The binding mainly affects nucleation, and 
the lag time was found to be strongly influenced by the copolymer composition. The 
binding is due to a combination of hydrophobicity (controlled via copolymer 
composition) and hydrogen bonding between polar groups on the polymer and in 
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A .
114
 In the case of cationically (amide) functionalized polystyrene nanoparticles, 
inhibition of fibrillization is observed for high particle surface area, whereas 
fibrillization is accelerated for low particle surface areas due to reduction of the lag 
phase.
306
  
 
Inorganic nanoparticles can function as A  fibrillization inhibitors,
307
 although this 
was demonstrated with cytotoxic CdTe nanoparticles. The precise mechanism is 
unclear. Polyoxometalates which comprise inorganic early transition metal clusters 
also inhibit the aggregation of A .
308
 Surprisingly, organic nanoparticles based on 
porous silica have been shown to penetrate the brains of fruit flies (D. melanogaster), 
without exhibiting neurotoxic effects and potentially enabling delivery across the 
BBB.
309
 BBB permeability can be modeled using the parallel artificial membrane 
permeability assay, which measures passive diffusion of small molecule through an 
artificial lipid membrane.
262,310
  
 
One example of a study using dendrimer molecules employed maltose-functionalized 
dendrimers to influence the fibrillization of A 40.
311
 A smaller dendrimer led to 
fibrillar clumps, sequestering the A  and reducing toxicity, whereas a larger one 
produced amorphous aggregates, toxic to cells. 
 
3.3 Inhibitors of the secretase enzymes 
It has proved difficult to identify small molecule inhibitors of -secretase (BACE1) 
with favorable pharmacokinetic characteristics.
242a
 The crystal structure of -secretase 
complexed to an 8-residue peptide inhibitor EVNLAAEF has been reported – the 
enzyme has the usual binding cleft of an aspartyl protease.
312
 A Japanese group have 
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developed several peptide-based compounds based on phenylnorstatine.
313
 A lead 
compound KMI-429
313b
 was explored further in vivo using a mouse model.
314
 Since 
the enzyme is membrane bound, an inhibitor has recently been developed by linking a 
peptide -secretase inhibitor to a sterol moiety designed to insert in the membrane.
315
 
Statins may be used to inhibit cholesterol biosynthesis and the expression of BACE 
and ultimately A  production.
316
 Statins can inhibit the dimerization of BACE by 
inhibiting lipidation.
317
 This may provide a therapeutic target to reduce A  
production. The role of protein-protein interactions in the correct assembly of BACE, 
which is required for A  production has been discussed.
317
 BACE associates with 
APP in cholesterol-rich rafts.
318
 Knocking out the -secretase gene BACE1 causes no 
adverse phenotype in mice,
319
 indicating that -secretase inhibitors may still provide 
an attractive target for treatments. 
 
A greater number of compounds have been developed as potential inhibitors of -
secretase. A complicating factor here is that NOTCH1 and other ligands are also -
secretase substrates (as well as APP)
242a
 and therefore Notch-related side effects may 
be problematic.
320
 However, certain non-steroidal  anti-inflammatory drugs (NSAIDs) 
can modulate -secretase cleavage without blocking Notch cleavage.
321
 Some 
NSAIDs can reduce A  levels independent of cyclooxygenase (COX enzyme, 
associated with inflammation) activity.
321a-c
 Application of NSAIDs including 
ibuprofen, flurbiprofen and indomethicin inhibits the release of amyloidogenic A 42 
from cultured cells.
321a
 Flurbiprofen (Fig.13d, in the R enantiomeric form, shown to 
be particularly effective
322
) reached phase III clinical trials, but these were 
unsuccessful. The target of -secretase modulators, such as flurbiprofen and related 
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compounds, has been located to A (28-36) based on investigation of the localization 
of fluorescently labeled and biotinylated variants of these NSAIDs.
321e
 Some -
secretase modulators were shown to alter the production of cell-derived A  
oligomers
321e
 while compounds that interact with this region of A  act as -secretase 
inhibitors, highlighting the interplay between -secretase-influenced A  production 
and A  aggregation.
321e
 Furthermore, since some NSAIDs bind to to an APP substrate 
rather than -secretase, Notch toxicity may be avoided in this way.
321e
 
 
The -secretase inhibitor Semagacestat (Fig.13e) was shown to reduce formation of 
A  in cell assays and also in vivo studies.
205,323
 Lanz et al. show that this compound 
leads to lowering of A  in plasma (in guinea pigs) at low doses, but an elevation of 
A  levels at low concentrations.
323
 However, Semagacestat was not successful (due to 
inferior performance relative to placebo) in phase III clinical trials. 
 
Other strategies have been employed to avoid side effects from Notch impairment. 
Other than NSAIDs, -secretase inhibitors that block A  production without 
influencing Notch activity such as the thiophene sulfonamide Begacestat (Fig.13f) 
have reached clinical trials, although the mechanisms are unclear.
324
 Serneels et al. 
have targeted specific components of the -secretase complex (Section 2.2.3), 
specifically produced by two APH1 (APH1A and APH1B) genes.
325
 Inactivation of the 
Alph1B complex decreases A  plaque deposition and improves behavioural deficits. 
The different Alph1 complexes also produce A  of different length.
325
 As an 
alternative to targeting -secretase, the reduction of -secretase-activating protein 
(GSAP) has been shown to decrease A  production in cells and in vivo using a mouse 
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model.
326
 The anticancer drug imatinib (Gleevec, Novartis) is able to inhibit A  
production without affecting Notch cleavage since it prevents interaction of GSAP 
with the -secretase substrate. Thus, GSAP is a potential selective therapeutic target 
avoiding side effects associated with -secretase inhibition.
326
 Phiel et al. showed that 
therapeutically relevant doses of lithium chloride, a GSK-3 inhibitor, block the 
production of A  peptides by interfering with APP cleavage at the -secretase step, 
but do not inhibit Notch processing.
46
 
 
3.4. Immunization 
In the development of A -based immunotherapies, several strategies have been 
pursued including passive immunization with monoclonal anti-A  antibodies, active 
immunization with synthetic A 42 and active immunization with modified A  
fragments (Fig.16).
327
 Progress with active immunization has been dogged by the 
failure of phase IIa clinical trials due to the development of meningoencephalitis in 
several patients (vide infra). 
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Fig.16. Antibody strategies.
327a
 Three different approaches are illustrated. The first 
(panel a) involves immunization with full-length A 42. After injection, the peptide is 
taken up by antigen-presenting cells, and fragments of the peptide are presented to T 
cells. Subsequently, various B cells that recognize epitopes on A 42 are engaged and 
proliferate. These eventually produce anti-A  antibodies. The second active 
immunization method (panel b) involves administration of small fragments of A  
conjugated to an unrelated carrier protein. This approach is similar to the first with the 
exception that the T cells are stimulated by the carrier protein rather than the A  
fragment (which lacks T cell epitopes). This approach yields a strong antibody 
response to part of the A  peptide. The third strategy (panel c) is to administer anti-
A  antibodies directly. This does not require any immunological response from the 
host and might be useful in individuals in which an immune response is not otherwise 
produced. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Neuroscience 3, 824, copyright 2002. 
 
 
Active immunization of transgenic mice with fibrillar A 42 leads to a reduction in A  
deposits in the brain (mouse model) and prevents development of plaque pathology 
when administered before its formation.
83c,328
 The A  antibodies generated were 
reported to reduced A  plaque deposition without reducing overall A  levels.
84a,329
 
An improvement in the cognitive performance of mice was also noted. 
84a,329
 Phase IIa 
trials pursued by Elan pharmaceuticals, based on this approach (using aggregated 
A 42 termed AN1792 with an immunogenic adjuvant QS-21) were halted when 6% 
of patients developed meningoencephalitis.
327a,328,330
 However, after one year patients 
producing antibodies that targeted plaques had a lower rate of cognitive decline.
328
 In 
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further follow-up studies it was found that there was a reduction in CSF tau levels 
following A 42 immunization.
331
 and a decrease in brain volume.
332
 Although 
clearance of A  plaques occurred, this did not prevent neurodegeneration.
333
 Using a 
triply transgenic mouse (3xTg) model it has been shown that A  immunotherapy can 
not only reduce A  plaques, but also early hyperphosphorylated tau pathology.
334
 
Vaccination with soluble oligomers of A 42 has also been proposed as a method to 
produce toxicity-reducing antibodies.
204
 Intraperitoneal injection of A -laden brain 
extracts into the brains of transgenic mice leads to the deposition of amyloid plaques 
after prolonged incubation time.
335
 These observations point to the possible prion-like 
behaviour of A  and the need for great caution (at the very least) in the development 
of immunization using A  directly.  
 
Sigurdsson et al. 
336
 investigated immunization using the modified peptide K6A (1-
30)-NH2, with an N-terminal hexa-lysine extension to A (1-30), the oligo(lysine) 
enhancing immunogenicity, this extension following work by Palitto et al.
282
 (section 
3.2.1). Using a transgenic APP mouse model, this peptide was found to reduce the 
burden of hippocampal and cortical A , and more particularly the amount of soluble 
A 42 in brain tissue.
336
  
 
Passive immunization using antibodies prevents amyloid formation by brain extract 
from AD patients or APP23 transgenic mice (which over-express A 40 which 
deposits in diffuse and filamentous form), pointing to the suppression of seeding 
activity.
89
 It has been suggested that A  disrupts the integrity of the BBB and that this 
is restored after immunization as the immune system clears A  from the brain.
337
 The 
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ability of A 40 to cross the BBB and increase its permeability had been observed 
earlier, using a cell culture model.
338
  
 
Passive immunization using the humanized monoclonal antibody bapineuzumab 
against A  got as far as phase II clinical trials.
339
 However, no significant benefit was 
observed in cognitive performance tests, and in addition some patients exhibited 
vasogenic edema.
339a
 However, this compound continues to be investigated in 
ongoing phase III trials.
14b,279a,340
 as is the related compound solaneuzumab.
14b,279a,341
 
Passive immunization using monoclonal antibodies (mAbs) has been investigated by 
Solomon et al.
190b,342
 They found via in vitro studies that selected mAbs prevent the 
aggregation of A , antibodies recognizing epitopes within A (1-28) and A (8-17).
342
 
Antibodies raised against A (1-28) can disaggregate A  fibrils in vitro and reduce the 
neurotoxic effects of A  in vivo (MTT cytotoxicity assays using PC12 cells).
190b
  
Antibodies selectively directed against residues 4–10 of Aβ42, inhibit both Aβ 
fibrillogenesis and cytotoxicity without eliciting an inflammatory response, in 
addition they can disaggregate preformed A 42 fibrils.
195
 De Mattos et al. showed 
that an antibody (m266, Table 3) against A 40 is able to bind and completely 
sequester plasma A .
188a
 Peripheral administration leads to a large and rapid increase 
in plasma A  due to a change in A  equilibrium in plasma and in CNS. The m266 
antibody does not bind to A  deposits in the brain.
188a
 However, using mouse anti-A  
IgG1 antibodies (recognizing A (1-16)) some clearance of compact amyloid deposits 
is observed after several days, along with microglial activation.
86
 The increase in 
plasma A  levels was correlated to A  load in the hippocampus and cortex (of 
PDAPP mice) after immunization.
103
 Administration of m266 to PDAPP can improve 
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cognitive learning, despite no alteration in brain A  burden.
343
 A complex of m266 
and A  was found in the plasma and CSF of treated mice. Bard et al.
344
 noted the 
presence of anti-A  antibodies in the central nervous system after peripheral 
administration, which were able to bind A  plaques and to reduce the pre-existing A  
burden. The mechanisms of clearance of A  in vivo by immunotherapy have been 
investigated, this showed that direct disruption of plaques as well as Fc-dependent 
phagocytosis was involved.
345
  
 
Immunization using antibodies to human serum amyloid P component leads to the 
elimination of visceral amyloid desposits, in mice.
346
 The plasma glycoprotein human 
serum amyloid P (SAP) component non-selectively binds all kinds of amyloid 
deposits.
347
 Clinically, it is possible to reduce circulating human SAP using a known 
SAP-depleting compound, thereby stimulating antibody production. Inhibitors of SAP 
binding to A  fibrils have also been developed, and the lead compound (CPHPC) also 
reduced levels of circulating human SAP.
346-348
 This technology is proceeding to 
human clinical trials.
349
 
 
3.5 Other Approaches 
Other treatment strategies are being pursued, these are discussed elsewhere
8,12a,31
 and 
are not considered further here as they do not involve A . Summaries of compounds 
in phase I, II and III clinical trials are available.
14,235,279
  
 
Due to a correlation between insulin resistance (section 2.1) and AD, the peroxisome 
proliferator-activated receptor-  (PPAR- ) agonist rosiglitazone has been investigated, 
51
 and has reached phase III trials.
31
 This compound is an insulin sensitizer and 
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mitochondrial activator, and it activates the PPAR-  pathway. This increases dendritic 
spin density and rescues spine loss caused by APOE- 4.
51
 Nerve Growth Factor 
(NGF) mimics have also reached phase III trials,
31
 however since this does not 
involve A  it is outside the scope of the present review. An antihistamine drug 
Dimebon
350
 reached phase III clinical trials for AD which failed due to the absence of 
a significant effect.
351
 The clearance of A  is facilitated by ApoE (section 2.1.1). This 
process is impaired in AD. The compound bexarotene that influences ApoE 
expression has been shown to enhance clearance of soluble A  in an ApoE-dependent 
manner, also improving cognitive performance in mice.
352
 
 
4. BIOPHYSICAL CHEMISTRY STUDIES OF A  AND FRAGMENT 
PEPTIDES– STRUCTURE AND AGGREGATION 
 
4.1 A  Conformation and Structure of Fibrils 
 
 
Amyloid fibrils contain bundles of -sheets with backbones orthogonal to the fibre 
axis, in the so-called “cross- ” structure (Fig.17), and this is observed in fibre X-ray 
diffraction (XRD) patterns obtained from stalks of A  and fragments. 
27a,27b,27d,27e,353
 
The prominent equatorial reflections in Fig.17a (a typical amyloid fibre XRD pattern) 
arise from the spacing of stacked -sheets (10-12 Å, the range of values arising from 
different side chain packing modes) and the meridional reflections arise from the -
strand spacing (4.7-4.8 Å). 
 
  
 
(a) (b)
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Fig.17. Fibre X-ray diffraction patterns from (a) A 40, (b) A (11-28).
353a
 Reprinted 
from Inouye, H. et al. Biophysical Journal 1993, 64, 502, Copyright 1993, with 
permission from Elsevier 
 
 
Many studies have analysed the conformational tendencies of A  and associated 
fragments. Early work is reviewed by Serpell
27d
 and others.
354
 A study using CD and 
NMR showed that A 40 in aqueous buffer solution adopts a predominantly 
polyproline II conformation at 0 
o
C and a random coil state at 60 
o
C.
355
 The residues 
in the central hydrophobic region A (12-28) tend to adopt -strand-like 
conformations at temperatures below 20 
o
C. The thermal PPII – random coil transition 
was found to be weakly cooperative. The conformation of the N terminal A (1-9) 
domain was also analysed.
355
 CD has also been exploited to examine the secondary 
structure formation of A (1-28), A (1-39), A 42 and A (29-42) in water and TFE or 
HFIP.
356
 In aqueous TFE, A 42, A (1-28) and A (1-39) adopt an -helical structure 
at low and high pH, but a -sheet structure at  intermediate pH.
356a
 A 42 and A  
have a net charge of +3 at pH 7.4 and -sheet formation is possible under these 
conditions. The solubility of A 42 and shorter peptides in aqueous solution was 
studied as a function of pH and concentration and aggregation was found to be 
enhanced at low pH.
90a
 Murphy and coworkers investigated the aggregation of A (1-
28), including the kinetics of aggregation via light scattering.
357
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Much effort has focussed on analysing the conformation of the core hydrophobic 
domain of A . NMR provides the most detailed conformational information. 
Benzinger et al. applied 
13
C cross-polarization magic angle spinning solid state NMR 
to probe the conformation of A (10-35).
358
 Multiple quantum analysis using the 
DRAWS pulse sequence enables the registry of specific labelled residues to be 
determined. This revealed a parallel -sheet structure with residues in register. The 
parallel in-register structure persists despite pH dependent variation in fibril 
morphology as revealed by electron microscopy.
359
 Similar solid state NMR 
techniques (with constraints from X-ray diffraction and TEM measurements) have 
indicated a parallel configuration of -strands of A 40, each molecule of which has a 
-strand/turn/ -strand arrangement (Fig.18).
360
 A similar parallel in-register 
arrangement was deduced from solid-state NMR data for A 42.
359
 A turn structure 
was located in the A (26-29) domain based on proteolysis of disulfide-bridged 
A (10-43) analogues.
361
 A turn was also predicted around residue 26, based on a 
primary sequence conformation index.
362
 This feature was also anticipated based on 
MD simulations of A (16-35) and A (10-35) that showed turns in the A (24-27) 
region due to intramolecular D23-K28 salt bridging.
363
 In contrast to A 40 and A 42 
which show in-register parallel -sheets, NMR studies reveal that Iowa mutant D23N 
A 40 can form antiparallel -sheets.
364
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Fig.18. Stacking of A 40 into parallel -sheets according to modelling with 
constraints from solid state NMR. Reprinted with permission from ref. 
360b,360c
. 
Copyright 2011 American Chemical Society.  
 
Detailed conformations of the -strand/turn/ -strand U-shaped arrangement have 
been compared for the Ma-Nussinov
363
 models and the NMR derived conformations 
of Lührs
365
 and Tycko.
360b,360c,366
 Replica-exchange molecular dynamics (REMD) and 
discrete molecular dynamics (DMD) simulations
367
 have also confirmed these 
features, as discussed in Section 4.2. Later MD simulations confirmed a turn in the 
A (23-28) domain.
368
 Benzinger et al. did not find evidence for a turn structure in the 
A (25-29) domain in their study of A (10-35),
358b
 highlighting the importance of the 
E22 and V24 residues in salt bridging and hydrophobic interactions respectively. An 
analysis of fibre X-ray diffraction data from A (11-25) fragments was also consistent 
with a hairpin turn structure, but in the L17-F20 domain.
353b
 However, in a later report 
from the same group, the unit cell was modelled based on an extended conformation 
of A (11-25).
369
  The -sheet structure of this peptide has been imaged by cryo-TEM 
which indicates in-register -strands.
370
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In contrast to work focussed on the core hydrophobic domain, there have been fewer 
studies on the conformation of the C terminal region. The hydrophobic C-terminal 
A (29-42) segment forms a -sheet structure independent of pH, solvent or 
temperature
356
 pointing to the high aggregation propensity of this domain, in 
agreement with computer simulations discussed above. The important role of the 
A (33-35) domain was also shown by Pike et al. who performed a thorough study on 
the secondary structure of variants (amino acid deletions and substitutions) of A (25-
35) via CD  and on the neurotoxicity of these peptides.
371
 These authors also imaged 
fibril morphology using electron microscopy.
371
 Aggregation of -sheets is found to 
be maximal at pH 5.4.
356b
 A low resolution NMR study indicated a pleated 
antiparallel -sheet structure for A (34-42).
372
 Hoyer and coworkers reported, on the 
basis of NMR and computer modelling, a -hairpin structure for A 40 in a complex 
with a phage-display selected affibody protein.
200
 The hairpin comprises residues 
A (17-36). On the other hand, SDS at pH 7.2 stabilizes an A 42 conformation 
comprising an extended chain (D1-G9), two -helices (Y10-V24 and K28- A42), and 
a looped region (G25-S26-N27) as revealed by solution NMR.
373
 Helical content of 
A (12-28) in the K16-V24 domain in presence of SDS is also confirmed by CD.
374
 
Figure 19 shows the -strand/turn/ -strand conformation of A (18-42) (residues 1-17 
are disordered) within the cross-  fibril structure. 
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Fig.19. Conformation of A (17-42) as revealed by H/D-exchange NMR.
365
 PDB: 
2BEG. The hydrophobic, polar, negatively charged and positively charged amino 
acids are shown in yellow, green, red and blue respectively. Positively and negatively 
charged surface patches are shown in blue and red, others in white. Copyright 2005 
National Academy of Sciences, USA. 
 
Disctinct from longer A  fragments (except the Iowa mutant, discussed above), the 
A (16-22) peptide appears to adopt an antiparallel -sheet arrangement as indicated 
by solid state NMR,
375
 and isotope-edited FTIR on labelled peptides (combined with 
ssNMR)
376
 and computer simulation.
363
  
 
The crystal structure of several A  fragments has recently been reported, specifically 
A (16-21) (for which three polymorphs were observed), A (27-32), A (29-34), 
A (30-35), A (35-42) (in two forms), A (35-40) (in two forms) and A (37-42).
377
 
These peptides all form steric zipper structures, i.e. based on self-complementary 
pairs of -sheets. Sequences prone to form steric zipper structures were screened 
using a 3D-profile self-association energy calculation, which indicated a cluster of 
aggregation-prone sequences in the C terminal A (30-42) domain.
377
 In the first 
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report by Eisenberg’s group on crystal structures of amyloid steric zipper structures 
A  peptides including A (37-42) GGVVIA and A (35-40) MVGGVV were among 
the peptides studied. 
378
 GGVVIA belongs to the class of parallel up-down face-to-
back -sheet structures while MVGGVV -sheets adopt an antiparallel up-down face-
to back arrangement.  
 
Based on cryo-TEM images, A 40 fibrils are reported to comprise two protofibrils 
whatever the overall fibril morphology (considerable polymorphism was noted, see 
also section 4.4).
379
 An initial report based on cryo-TEM suggests that A 42 forms 
hollow fibrils in which the hairpin A (17-42) regions fit within the reconstructed 
density map of the shell.
380
 However, a later report from the same group based also on 
cryo-TEM along with additional mass-per-length measurements from scanning TEM, 
indicates that A 42 forms a single filament structure without a hollow core 
(Fig.20).
381
 The cryo-TEM images published for A (11-25) also do not show a 
hollow interior.
370
 Malinchik et al. had earlier proposed a hollow filament structure 
for A 40 on the basis of TEM cross-section images on plastic-embedded samples, as 
well as analysis of XRD data.
382
 Although hollow fibrils were proposed as a common 
structure for amyloid fibrils,
383
 there is in now consensus that this is not the case, and 
A  fibrils are not hollow nanotubes, although these structures can be observed for 
fragments such as A (16-22) under appropriate conditions (section 4.5). On the other 
hand, MD simulations constrained by the cryo-TEM density maps for A 42, and 
NMR coordinates based on data from A 17-42) suggest that a hollow core structure 
might be relevant under physiological and acidic pH conditions.
384
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Fig.20. Electron density maps for A 40 and A 42, reconstructed from cryo-TEM 
images.
381
 Copyright 2009 National Academy of Sciences, USA. 
 
 
The extent of unfolding of A  and ultimately the fibril morphology seem to depend 
on the level of denaturation.
385
 By studying A 40 and A 42 in which the methionine 
(residue 35) side chain was in oxidised or reduced state, Hou et al. found on the basis 
of solution NMR, residue-specific interactions in the early stages of aggregation.
386
 
These authors suggest that both hydrophobic and turn-like structures are required in 
the first self-assembly steps. The solution structure of the methionine-oxidised form 
of A 40 has also been studied by NMR and CD by Craik and coworkers – random 
coil structures were observed at pH 4 in water.
387
 In SDS solutions, a helical region in 
the A (16-24) is noted for this peptide.
387
 The specific region of A 40 involved in 
contacts between fibrils has been identified by solution-state NMR, and corresponds 
to A (15-24).
388
  The NMR data also show that there is an exchange between a 
monomeric, soluble state and an oligomeric aggregated state under appropriate 
(physiological) conditions of salt concentration. The equilibrium can be shifted by 
varying anionic strength.
388
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4.2 Computer Simulations of A  Conformation and Aggregation 
 
This subject has recently been discussed in several reviews, and some aspects are 
mentioned in the preceeding section.
366,389
 Discrete molecular dynamics simulations 
using a four bead model (corresponding to different peptide sequences) with hydrogen 
bonding interactions have been used to model the oligomerization of A 40 and 
A 42.
390
 These simulations uncovered that the most common species are dimers for 
A 40 and pentamers for A 42, although oligomers up to 9-mers were found for each. 
These results may be compared with the experimental data on oligomer size 
distribution for these two A  peptides discussed in Section 2.6.2. Intramolecular 
contacts were analysed and a turn structure was proposed to stabilize the pentamer 
structure favoured by A 42.
390
 REMD has elucidated the conformation of A 42 in 
which loops and turns predominate, although helical regions are found near the C 
terminus.
391
 It was proposed that these helices are involved in the formation of the 
oligomeric paranucleus revealed by ion mobility mass spectrometry (Section 2.6.2).
391
 
 
The structure of A (17-42) protofilaments in solution has been modeled via MD 
simulations, along with the influence of mutations at E22 and M35.
392
 Steric zipper 
formation is observed due to favorable C- and N- terminal interface interactions. 
Double layered models of oligomers were constructed with association via CC or NN 
interfaces (Fig.21), these being stabilized by salt bridges. The U-shaped -
strand/turn/ -strand conformation (section 4.1) leads to a hydrophobic cavity within 
the stacked -sheets.
392
 All-atom MD simulations have been performed to elucidate 
the structural stability and conformational dynamics of A (9-40) for wild type and 
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mutated sequences.
368
 The peptides adopt in-register parallel -sheets. Salt bridges are 
formed between N23 and K28, solvated by water molecules, leading to a hydrated 
channel along the fibril axis.
368
 The results were compared to models based on solid 
state NMR data (section 4.1).
360b,360c
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.21. Double layer models used for A (17-42) oligomers.
392
 Top- association via C-
terminal interfaces; Bottom- association via N-terminal interfaces. Charged residues 
are shown in red and blue. Reprinted from Zheng, J. et al. Biophysical Journal 2007, 
93, 3046, Copyright 2007, with permission from Elsevier. 
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The oligomerization of A  peptide fragments A (16-22) and A (25-35) has been 
studied by all-atom Monte Carlo simulations.
393
 The aggregation of the weakly 
hydrophobic A (25-35) peptide is driven by the tendency to form hydrogen bonds 
that stabilize -sheets, and this peptide aggregates in a single step. The formation of a 
critical nucleus involving four peptides was noted for this peptide. In contrast, for the 
more hydrophobic A (16-22) peptide, initial collapse into disordered oligomers was 
observed. In these oligomers, hydrophobic residues are sequestered from the solvent. 
The subsequent reorganization of oligomers into -sheet aggregates involves inter-
chain H-bonding interactions and exposure of certain residues to solvent.
393
 MD 
simulations have eludicated the structure of dimers formed by A (25-35) with high -
sheet content aggregates coexisting with less structured dimers.
394
 The effect of the 
self-recognition KLVFF domain and the -sheet breaker peptide LPFFD on the 
oligomerization of A (16-22) was examined by all atom MD simulations.
395
 The 
binding domain near the N-terminal involving H13 was identified, and binding 
energies were calculated. LPFFD as expected has a greater inhibitory effect on 
aggregation.  
 
DMD simulations using a “united atom” model (specifying all atoms except 
hydrogens) have been performed to examine the conformation of A (21-30).
367b
 A 
hairpin conformation driven by hydrophobic interactions between V24 and the butyl 
units of K28, and stabilized by transient salt bridging between E22/N23 and K28, was 
identified.
367b
 REMD simulations have been carried out for the same fragment with 
similar conclusions.
367c
 The significance of the mutations at the E22 residue (Section 
2.2.4) in influencing the stability of turn structures, and hence of aggregation into 
toxic assemblies, was noted.
367c
 These observations are consistent with ssNMR 
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experiments as mentioned above and in the preceeding section. The results of REMD 
simulations on A (21-30) have been compared to ion mobility mass spectrometry 
data, in particular the collision cross-section can be modelled, providing information 
on conformation.
367e
 A particular focus was the turn structure and the influence of the 
E22G, E22Q, E22K and D23N mutations.
367e
 The same group also performed all-
atom MD simulations in explicit water of the folding of A (21-30) and the Dutch 
mutant with the E22Q substitution.
367a
 Similar conclusions were drawn concerning the 
presence of loops in the V24-K28 region in the wild-type peptide, although this is not 
observed for the Dutch mutant sequence. The influence of salt ions on the salt 
bridging interaction was examined.
367a
 
 
MD simulations have been used to investigate the adsorption of A (17-42) oligomers 
(from dimers to hexamers) onto self-assembled monolayers (SAMS) with different 
end-functional groups.
396
 The SAMS are proposed to serve as models for cell 
membranes. The simulations complement experimental studies (CD, AFM, SPR) on 
A 42 by the same group,
397
 which shows that fibrillization is accelerated in the 
presence of SAMs, to the greatest extent for the hydrophobic –CH3 capped SAMS or 
the cationic –NH2 functionalized SAMS. This observation points to the role of both 
hydrophobic and electrostatic interactions. The simulations suggest that trimers 
constitute the smallest nucleus that can seed A  polymerization. 
 
 
4.3 Kinetics and Mechanisms of Fibrillization 
 
 
4.3.1 Mechanisms 
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As mentioned in Section 2.2.1, A 42 is more aggregation prone and exhibits faster 
fibril growth than A 40. A detailed model for the aggregation into initial aggregates 
(oligomers, termed “micelles” in the original work) and subsequently fibrils has been 
developed.
398
 This permits nucleation and elongation rate constants to be calculated. 
 
Fibrillization of A  appears to occur via a proto- or pre- fibrillar stage.
6d,212,221a,399
 
These oligomeric species are consumed as fibrillization proceeds.
212,399a
  The pre-
fibrillar stage has been proposed to correspond to micelle formation. Fibrillization of 
A 40 occurs above a critical concentration which has been described in analogy with 
a critical micelle concentration (cmc) as shown in Fig.22.
6a,90b,400
 Fibrillization can be 
described using the corresponding one-dimensional model of self-assembly.
401
 The 
initially formed protofibrillar species for several proteins including A 40 and A 42 
are spherical annular-shaped species
212,221a,399b
 which may be linked into 
chains.
221a,399b
 The proto-fibril formation process may occur before or during the lag 
phase.  
 
conc. of peptide
conc.
of species
fibril
monomer
c
R
 
Fig.22. Amount of fibril and monomer as a function of added protein. Fibrils are 
formed above a critical concentration, cR. From ref. 
402
, redrawn from ref. 
6a
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Models that extend beyond the Oosawa-Asakura model
403
 for one-dimensional self-
assembly have been developed to describe more realistically amyloid aggregation 
kinetics.
404
 In particular, the influence of fragmentation, i.e. the generation of 
secondary nuclei, has been considered. It will be interesting to see this model applied 
to further analyse the kinetics of A  fibril growth. 
 
It is commonly observed that fibrillization occurs after a lag phase, suggesting a 
nucleation and growth process.
6a,90b,208,385a,400,405
 The lag phase can be eliminated by 
addition of pre-formed aggregates, i.e. by seeding (Fig.23).
6a,90b
 The influence of 
A 40 seeds on A 42 aggregation and vice versa has been examined using 
immobilized seeds.
406
 Oligomeric forms of the peptides were found to be more 
effective seeds than either monomers or fibrils and A 42 monomers aggregated onto 
A 42 fibrils more rapidly than other combinations. 
 
time
conc.
of fibrils
add seed
 
Fig.23. Addition of seed can eliminate the lag time in fibrillization. From ref. 
402
, 
redrawn from ref. 
6a
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AFM on A 40 and A 42 provide a picture of the initial formation of protofilaments 
followed by their replacement with fibrils,
212
 this technique being complemented with 
light scattering, and TEM and SEC analysis of the molecular weight of fractions 
obtained at different stages of the polymerization process.
399a
  
 
The aggregation of A  on planar substrates, hydrophilic mica and hydrophobic 
graphite, has been investigated. On mica, pseudo-micellar aggregates were noted at 
low concentration and fibrils at higher concentration. In contrast, on graphite, sheets 
were observed with a thickness equal to the extended peptide length, oriented along 
the graphite lattice directions.
212
 A later AFM study examined A 42 fibrillization and 
plaque formation, and the interaction between A 40 and A 42.
406
 Deposition was 
studied on a synthetic template comprising an N-hydroxysuccinimide ester-activated 
solid surface. A 42 oligomers were found to be more effective seeds for fibril growth 
than monomers or mature fibrils. 
 
Lin and coworkers investigated the kinetics and mechanisms of A 40 fibrillization 
under different conditions including variable temperature, ionic strength and pH.
407
 
The rate of fibrillization was enhanced with increasing temperature or ionic strength. 
A two-state mechanism of growth was proposed, nucleation being the rate-
determining step. The aggregation mechanism was dependent on ionic strength since 
addition of monomers to fibrils can occur either at the ends (at low ionic strength), or 
depending on screening of electrostatic interactions at high ionic strength, by lateral 
aggregation.
407
 Linse et al. suggest that A 42 (D1M mutant) fibrillization occurs via a 
two-phase state involving soluble A  (liquid phase) and aggregated A  (solid 
phase).
408
 They used ThT fluorescence and ELISA to monitor fibril growth, and free 
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A  concentration respectively. The free A  concentration varied linearly with total 
A  concentration up to 0.2 M, followed by a decrease to an asymptotic value. This 
suggests a cmc of 0.2 M in the buffer conditions examined.
408
 These authors also 
point to the need to be extremely careful with the preparation conditions to obtain 
reproducible fibrillization data on A 42 due to the known complications associated 
with avoiding initial A  aggregation (for example, aggregation of A 40 even on resin 
during solid phase synthesis has been observed by SSNMR
409
) as well as nucleation at 
interfaces (air/water interface of bubbles, surface of vessel).
408
 It is already known 
that very careful protocols have to be followed in studying fibrillization of A  for 
example, for example starting from a well-defined state of unaggregated peptide 
(achieved by initial dissolution in a hydrophobic solvent) and then carefully 
controlling the addition of water or buffer to a dried film, as discussed in Section 
2.6.2.
214
 Agitation, e.g. via sonication, is known to have a particularly marked effect 
on fibril morphology and indeed can be used to create specific polymorphs.
364,410
 
 
Exchange dynamics between monomers and NMR-invisible (dark state) protofibrils 
of A 40 and A 42 have been investigated using single residue 
15
N dark-state 
exchange saturation transfer NMR.
411
 This revealed that the first 8 residues at the N 
terminus exist in a mobile tethered state while the hydrophobic central residues are 
either tethered to, or in contact with, the protofibril surface. The C terminal residues 
display lower affinity for the protofibril surface. The 
15
N relaxation rates of the C 
terminus residues are larger for A 42 than A 40 and this was proposed as an 
explanation for the higher fibrillization rate of the former peptide.
411
 
 
4.3.2 Kinetics 
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In the growth state of fibrillization, early work on A 40 suggested that the kinetics 
are first order, i.e. the rate of fibril elongation is proportional to the concentration of 
monomers.
400,412
 This was confirmed via light scattering on A 40 in 0.1 M HCl
400
 
(aggregation kinetics are pH dependent), in vitro studies of deposition onto plaques in 
unfixed Alzheimers disease brain tissue
412a
 and ThT fluorescence studies.
412b
 
However, in the absence of seeds, A  aggregation exhibits faster than first order 
kinetics and an optimal pH of 5 instead of 7 as for templated aggregation.
412a
 The 
temperature dependence of fibril extension for A 40 in 0.1 M HCl (determined from 
size measurements via dynamic light scattering) follows the Arrhenius equation,
413
 
with an activation energy 96 kJ mol
-1
, comparable to the value for unfolding of 
several other peptides.
413
 The concentration dependence of fibrillization kinetics was 
also analysed. Light scattering has also been used to monitor the aggregation of A 40 
in PBS at different concentrations, and the size and shape of (proto-)fibrils was 
analysed,
414
 and previously, in a similar fashion, this method was applied for A (1-
28) 
357
 and A (1-39).
415
 
 
The rate of fibrillization is strongly influenced by seeding.
90b
 Fibril morphology is 
also influenced by seeding, as revealed by TEM and solid state NMR studies on A 40 
(see also section 4.4).
410
 The kinetics of A  fibril growth by covalent attachment of 
seeds to the surface can be monitored using using quartz crystal microbalance 
(QCM),
246,416
 surface plasmon resonance (SPR)
417
 or AFM
418
 techniques. Peptide can 
be immobilized on the QCM crystal via, for example, attachment of the peptide N-
terminus to a tethered 16-mercaptohexadecanoic acid monolayer (via carbodiimide/N-
hydroxysuccinimide activation) or biotinylated peptide attached via avidin.
416b
 The 
rate of elongation is observed as a change in resonant frequency of the crystal which 
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correlates to an increase in surface-bound mass. In this way, monomer addition to 
A 40 fibrils was studied, these were found to elongate in a reversible fashion with a 
rate that varies with monomer concentration and immobilized seed density.
416b
 The 
growth was consistent with a first-order kinetic model for the single growth phase 
observed. 
 
Rate constants have been determined for A  fibril growth using several methods. 
Direct comparison between results from these measurements is often not possible, due 
to differences in the precise definition of the measured quantity. Based on 2D studies 
using immobilized A 40, the following values were reported for the rates of 
association and dissocation: kass = 3.6 10
-4
 M
-1
 min
-1
, kdis = 7.6 10
-5
 min
-1
 and the 
association constant Kd = kdis/kass = 210 nM.
416b
 On the other hand, based on isotope 
exchange ESI-MS experiments on the dissociation of molecules from fibrils, the 
following values were determined for A 42: kdis = 0.01 min
-1
 for A 40 and kdis = 
1.67 10
-4
 s
-1
 for A 42.
419
 Linse et al. studied fibrillization of A (M1-40) on 
polymeric nanoparticles and reported kass = 0.13-0.28 min
-1
, with a lag time 37-250 
min.
114
 
 
Wetzel gives rate constants as shown in Table 4.
417,420
 These measurments were based 
on surface plasmon resonance measurements using immobilized seeds and may not 
represent bulk values. 
 
Table 4. Rate constants for dissociation and association determined by Wetzel and 
coworkers
417,420
 in the rapid reversible binding of monomer to the fibril in step 1 is 
follwed by two successive relatively slow processes (steps 2 and 3). 
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Mechanistic 
Step 
kdis 
(s
-1
) 
kass 
 
1 8.1 10
-1
 6.6 10
3 
M
-1
s
-1
 
2 4.4 10
-3
 6.4 10
-2
 s
-1
 
3 4.3 10
-4
 4.6 10
-3
 s
-1
 
 
 
Lomakin et al. 
398
 obtained for A 40 at pH 2 (0.1M HCl) a fiber nucleation rate kn = 
2.4  10
-6
 s
-1
 and elongation rate ke = 90 M
-1
 s
-1
. These authors propose mechanisms of 
fibrillization of A 40 under these conditions depending on whether the concentration 
exceeds the cmc, c* (Section 4.6) or not, as illustrated in Fig.24.
400
   
 
 
 
Fig.24. A) Homogeneous nucleation for c > cmc via formation of initial nuclei (rate 
constant kn) followed by extension, rate constant ke. Initially monomers associate into 
micelles with Rh = 7 nm, B) Heterogeneous nucleation for c < cmc, nucleation occurs 
mainly on seeds not comprising A . Figure from ref.
400
 Copyright 1996 National 
Academy of Sciences, USA. 
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Inouye and Kirschner
421
 analysed the kinetics of Congo red binding to A 40 at pH 
5.8, based on the measurements by Wood et al.
422
 Using the Oosawa-Asakura model 
for one-dimensional self-assembly, they obtained values for the dissociation constant 
for spontaneous assembly of Kd = 55.1 M and kdis = 2 h
-1
 (Kd = 53.7 M and kdis = 5 
h
-1
 for seeded assembly) as well as the rate coefficient and proton dissociation 
constant.
421
 The authors note that the kinetics of seeded fibril formation at pH 5.8 are 
faster than observed by Lomakin et al. 
400
 at pH 2.  
 
 
4.3.3 Thermodynamics 
Wetzel et al. have analysed the thermodynamics of amyloid fibrillization.
420
 The free 
energy of fibril elongation of wild type A 40 was found to be approximately -37.7 kJ 
mol
-1
.
420
 This group note that seeded fibril growth can be described as a 
dissociation/elongation equilibrium. The equilibrium is achieved with a remaining 
pool of monomer with a concentration of 0.7 – 1 M (corresponding to the cmc).420 
The equilibrium constant Kd was found to be around 0.8 – 1 M (the value being 
higher for mutants, and for fibril growth in the presence of ThT). A three step 
mechanism for elongation was proposed with three different sets of 
dissocation/association constants as described in the preceeding section.
420
 The 
change in Gibbs energy for a series of mutants of A 40 was analysed in a similar 
fashion.
423
 The exchange of A  molecules due to fibril association and dissociation 
has been monitored via hydrogen/deuterium exchange electrospray ionization mass 
spectrometry.
419
 Molecular recycling was found to be much more prevalent for A 40 
than for A 42. The free energy of fibril growth for A 40 can been determined from 
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the critical concentration (Section 4.6) and this leads to 0elG  = -46.1 kJ mol
-1
,
424
 in 
reasonable agreement with the value from Wetzel’s study quoted above. The Wetzel 
group also studied the effect of A 40 alanine mutations on the free energy of 
elongation.
424
 By measuring the amount of soluble monomer, and total protein 
concentrations at steady state for a series of amyloid forming proteins including A  
and others, the free energy of elongation was determined and these values may be 
compared with those for A 40.
425
 A correlation with the number of residues in the 
peptide was noted. 
 
4.3.4. Lack of Sequence Specificity in A  Aggregation 
The cross-  structure (Section 4.1) is a common feature for amyloids formed by many 
different proteins and peptides, including A .
2d,39b,426
 Evidence that formation of 
amyloid fibrils is a common state for many if not all proteins comes from several 
types of experiments. First, fibrils can be induced to form by partial denaturing of 
proteins not involved with any disease
427
 or using de novo designed peptide fragments 
(see Section 4.5). Secondly, amyloids can be induced to form by seeding with fibrils 
of the same, related or unrelated protein,
6a,89,385a,405b,428
 a process that may be 
implicated in the transmission of prion diseases,
6a
 although the transmission of 
spongiform encephalopathies may involve cofactors in addition to prions, the full 
mechanism being unclear as yet.
429
  
 
A study of mutants of A 40 (including Dutch type, Section 2.2.4, but also variants for 
rodents compared to primates) revealed that N-terminal substitutions that distinguish 
primate A 40 from rodent A 40 do not have a significant effect on fibril 
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morphology.
430
 The fibrils formed by the Dutch mutant were found to have enhanced 
stability at high pH compared to the other variants. 
 
Using fusion constructs with green fluorescent protein (GFP), libraries of mutants of 
wild-type A 42 have been prepared in which hydrophobic residues at the C 
terminus
431
 or 8-12 other residues in the C terminal domain
432
 have been substituted 
with random nonpolar residues. The folding and fluorescence of GFP is prevented by 
A 42, and mutations in A 42 that disrupt aggregation then lead to increased 
fluorescence.
433
 It was shown that fibrillization is promoted with hydrophobic 
residues at positions 41 and 42.
431
 and all the hydrophobic mutations (8-12 
residues).
432
 This implies that generic hydrophobic sequences may be sufficient to 
promote A 42 fibrillization.
432
 In related work, A 42-GFP fusion constructs with 
A 42 mutations across the whole sequence were expressed and A 42 aggregation 
was probed. This also identified key hydrophobic sequences involved in 
fibrillization.
433
 
 
 
4.4 Polymorphism 
 
 
The morphology of A  fibrils can be controlled through the growth conditions, and 
seeding, leading to distinct polymorphism. This in turn is related to the selection of 
specific conformations.
389b
 An important contribution on the subject of polymorphism 
was the study by Petkova et al.
410
 on A 40 polymorphism, controlled through 
application of sonication or not, and imaged by TEM (Fig.25). Solid state NMR was 
used to identify cross-correlations between different residues, i.e. to probe 
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conformations in different polymorphs. The cytotoxicity towards rat neurons was also 
shown to depend on A 40 polymorphism. In vivo, the phenotype of seeded 
amyloidosis depends on both the source and the host.
89
 This was examined using 
APP23 and APPPS1 transgenic mice, which overexpress A 40 and A 42 
respectively.  It was suggested that the dependence of amyloid morphology on the 
seed indicates the existence of A  polymorphism with associated distinct polymorph 
biological activity, reminiscent of prion strains.
89
  
 
 
Fig.25. Polymorphism of A 40 fibrils.
410
 From Petkova, A. T. et al., Science 2005, 
307, 262. Reprinted with permission from AAAS. 
 
Tycko’s group have recently shown that the polymorphism of A 40 (Iowa mutant) 
can be reduced by repeated seeding (up to nine generations were studied), which can 
be used to amplify a particular polymorph, even when it is initially a minor 
component.
364
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Seeds comprising nanotubes (self-assembled in methanol) of the modified peptide 
AAKLVFF (containing A (16-20), KLVFF) can seed nanotube formation in aqueous 
solution (conditions that favour non-nanotube fibrillization of unseeded peptide).
434
 
TEM was complemented by solid-state NMR which probed differences in the strand 
registry and residue packing in the nanotubes and fibrils. These observations point to 
the non-equilibrium nature of the seeded polymorphism.  
 
The factors that can influence amyloid fibril polymorphism are complex, and apart 
from factors such as agitation during sample preparation, the presence of hydrophobic 
interfaces or the air-water interface can influence fibrillization.
435
 
 
4.5 Fragments 
The fibrillization of fragments of A 40 and A 42 has been extensively investigated. 
Several early studies are summarized by Teplow
6b
 and Serpell.
27d
  
 
Aggregation-prone sequences in A  have been identified by computer modelling of 
measures of -sheet forming propensity. The TANGO algorithm, based on a 
statistical mechanical model of protein conformation (based on measures of 
propensity to form defined secondary structures), predicts a strong tendency for 
aggregation of A (17-21) and A (31-36), with enhanced aggregation of A 42 
compared to A 40.
436
 It can also account for the aggregation propensity of some of 
the mutant forms of A  (Section 2.2.4). The Zyggregator algorithm is based on 
measures such as hydrophobicity and patterning of hydrophobic residues that lead to a 
parameter set obtained by screening of sequences in protein databases.
437
 It predicts a 
strong tendency for aggregation of A (15-23) and A (30-42), i.e. similar domains as 
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indicated by TANGO.
202c,437
 These predictions have been compared to results from 
solid state NMR experiments for both protofibrils and mature fibrils and protofibrils 
are found generally to have shorter aggregation domains.
438
 
 
Several key regions are associated with aggregation propensity, including the 
transmembrane hydrophobic domain and the C-terminal hydrophobic domain. In the 
following, we focus on fibrillization by the shortest core fragment critical to fibril 
formation which is believed to lie in the A (16-22), KLVFFAE, region. Sequences in 
this central region of A 42 are of great interest because cleavage by the enzyme -
secretase occurs between K and L.
2a
 Hilbich et al. showed that a region in the 
hydrophobic core around residues 17 to 20, i.e. LVFF, is crucial for -sheet 
formation.
439
 They prepared variants of A 43, with substitution of various residues 17 
to 20, and investigated fibrillization by CD, FTIR and TEM. Substitution with 
hydrophilic amino acids led to a significant reduction in amyloid formation. Tjernberg 
et al. studied the binding of fragments and variant fragments of A 40 to the full 
peptide.
440
 Binding of 
125
I-labelled A 40 was studied by autoradiography. A series of 
fragments of A 40 ranging from 3 to 10 residues was prepared. Only pentapeptides or 
longer showed significant binding to A 40, and fragment A (16-20), i.e. KLVFF, is 
contained in all strongly binding sequences.
440b
 By preparing pentapeptide variants of 
KLVFF with substituted amino acids, it was found that residues 1, 2 and 5 (K, L, F) 
are most important for binding of this fragment to A 40.
440
 A model for the binding 
of KLVFF to A (13-23) confirmed the importance of these residues in forming an 
anti-parallel -sheet. The binding capacity of pentapeptides containing D-amino acids 
instead of L-amino acids was also studied, since the latter are resistant to proteolysis. 
Residues 2 and 3 were found to be most critical for binding, D-Lys, D-Phe enhancing 
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binding.
440b
 Findeis et al. presented a very thorough study on A -based inhibitors of 
A  fibrillization.
280
 This revealed again the importance of the A (16-21) region. A 
derivative of A (17-21), cholyl-LVFFA-OH was found to be a particularly potent 
inhibitor of fibrillization, although with limited biochemical stability. The D-amino 
acid version however was found to be stable in monkey cerebrospinal fluid. Other 
researchers have explored the role of molecular architecture on the inhibition of 
fibrillization. Dendritic tetramers containing terminal KLVFF motifs inhibit the 
aggregation of low molecular weight and protofibrillar A (1-42) into fibrils, 
substantially more than the linear KLVFF peptide.
441
 Recently, bifunctional 
molecules with terminal KLVFF pentapeptides linked by aminohexanoic acid spacers, 
have been shown to recognise early A  oligomers, manly trimers and tetramers, in 
mixtures.
442
 The molecules may act as “tweezers”, binding small oligomers if the 
central spacer has the correct length. 
 
The dependence of fibrillization on fragment size was investigated for A  fragments 
containing the A 16-20) sequence.
443
 Electron microscopy suggested that the 
shortest fibril-forming sequence was A (14-23), i.e. the decapeptide HQKLVFFAED. 
The KLVFF sequence was found not to form fibrils itself. However, more recent 
work shows that this peptide does form -sheet fibrils under appropriate conditions in 
aqueous solution.
444
 Meredith and coworkers later studied variants of KLVFF
284
 and 
KLVFFAE
445
 in which amide protons in alternate residues were replaced by N-methyl 
groups.
284,445
 Ac-K(Me)LV(Me)FF-NH2 was shown to form extended -strands.
284
 It 
is also more water soluble than KLVFF and can permeate phospholipid vesicles and 
cell membranes. This variant is also resistant to denaturation by addition of solvent, 
increase of temperature or pH.  It is also a potent inhibitor of A 40 fibrillization, and 
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can break up preformed A 40 fibrils, being more effective than KLVFF in both 
regards
284
 (as is heptapeptide NH2-KLV(Me)F(Me)F(Me)A(Me)E-CONH2
445
). These 
fragments are believed to form -strands with distinct faces – one with unmodified 
groups capable of forming hydrogen bonds and the other containing non-polar methyl 
groups. This can disrupt the hydrogen bonded -sheet structure of the A  peptide 
itself.  
 
Other fragments have been designed to inhibit A 40 and A 42 fibrillization. Rational 
design principles based on the knowledge of the pentapeptide binding sequence led to 
a study on LPFFD,
446
 now known as the -sheet breaker peptide. This peptide 
incorporates proline, known to be a -sheet blocker and was found to reduce amyloid 
deposition in vivo (rat model) and to disassemble pre-formed fibrils in vitro.
446
 Prior 
investigations of A (12-26) with proline substitutions had shown that Pro 
replacement of any residue in the A (17-23) LVFFAED sequence leads to a loss of 
fibril formation
447
 and this was confirmed via F19P substitution in A 42, although 
oligomeric species were still detected.
217
 This observation also points to the role of 
Pro residues in forming the core of -sheets. The capped version of the -breaker 
peptide, CH3CO-LPFFD-CONH2, has been shown to improve spatial learning in a rat 
model.
448
  
 
The retro-inverse peptide ffvlk (lower case indicates D-amino acids) binds A 40 
fibrils with moderate affinity but this binding can be significantly enhanced by 
attaching multiple copies of this peptide to an eight-arm branched PEG. 
449
 Tandem 
dimers of ffvlk linked by a k( A) (k denotes D-lysine) spacer or a difunctional PEG 
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chain also showed some enhancement of binding. All of these conjugates are effective 
in inhibiting fibrillization of the full A 40 peptide.
449
  
 
TEM indicated that KLVFF itself forms fibrils in aqueous PBS solutions (pH 7.4),
284
 
contrary to the reports by Tjernberg et al.
443
 There existed some controversy as to 
whether this fragment itself fibrillizes. This was resolved in a study which used 
cryogenic-TEM (cryo-TEM) among other techniques to confirm that KLVFF does 
form amyloid fibrils in aqueous solution, at sufficiently high concentration.
444
 Cryo-
TEM importantly avoids artifacts when drying to prepare samples for conventional 
negative stain TEM, this can be problematic in the case of weakly fibrillizing 
peptides. Fibril formation has been reported for the heptapeptide A (16-22), CH3CO-
KLVFFAE-NH2.
375
 It has been suggested that “fibrils” of this peptide actually 
comprise nanotubes, based on electron microscopy, atomic force microscopy and 
small-angle scattering data, and a detailed model for the lamination of the -sheets in 
the nanotube wall has been proposed.
450
 The related capped peptide A (16-22) E22L 
self-assembles into nanotubes in water/acetonitrile solution and the grooved surfaces 
of these were used to probe the binding of Congo red, which was found to bind 
parallel to the long axis.
451
 Analysis of the 3D structure of A 42 from NMR 
(discussed in detail in section 4.1) indicates that residues A (18-26) form a -sheet as 
do residues 31-42 within the overall -strand/turn/ -strand structure of residues 18-42 
as shown in Fig.19 (residues 1-17 are disordered).
365
 The sequence A (17-23) which 
seems to be vital in amyloid self-assembly has also been shown to be important in 
forming the correct -pleated sheet structure of the A peptide.
439,447
 As discussed in 
section 4.2, computer modelling predicts that A (17-21) should be prone to -sheet 
aggregation.
202c,452
 Using algorithms based on the aggregation properties of the 
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constituent amino acids, Kallberg et al.
453
 suggest that A (16-23) is a so-called 
discordant sequence of amino acids, in the sense that this sequence is predicted to 
adopt a -strand conformation, whereas the full protein structure in the protein data 
base (ref 1ba6) indicates an -helix for this region of A 40. The protein database 
structure 1ba6
387
 is for A 40 with oxidised methionine (residue 35) in aqueous SDS 
solution, a solvent which is known to favour -helices, observed between residues 16 
and 24 (section 4.1). NMR data on A 40 in aqueous solution also indicate an -helix 
for residues 15-24 in a water/TFE solution
454
 and for residues 1-36 in SDS solution
455
 
(the data from Sticht et al.
454
 gives pdb structure 1AML). As mentioned in Section 
4.1, NMR in aqueous solution
365
 indicates a -sheet in this region of A 42. Different 
methods to predict secondary structure indeed lead to different predictions for the 
conformation of KLVFF. The method of Garnier predicts -helices for KLVFF, 
whereas the Chou-Fasman method predicts residues KLV are in -strand and FF in -
helix structures.
202c
 A (9-11), i.e. NH2-GYE-OH, forms amyloid-like fibrils in 
aqueous solution.
456
 MTT assays indicate that the peptide is toxic to neurons. 
 
N-terminal variants of A  may also play an important role in AD pathophysiology. 
192,457
 Hilbich et al. used CD and EM to investigate the fibril-forming properties of 
A 43 and N-terminal truncated variants along with variants of A (10-23) with 
substitution of hydrophobic residues.
361
 Peptides in which phenylalanine residues are 
substituted for less hydrophobic residues show an enhanced solubility in salt solution 
compared to the native sequence. These authors also investigated variants in which 
pairs of residues (D23K28, V24G29, G25A30) in the A (10-43) peptide were 
replaced by pairs of cysteines, in order to examine the influence of disulfide bridging, 
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i.e. to fix an artificial turn structure. As discussed in section 4.1, the native peptide is 
believed to adopt a turn structure in the A (23-30) domain.
361
 
 
The fibrillization of A  variants with N-terminal glutamines replaced with 
pyroglutamyl residues has been investigated. Peptides with this form of post-
transcriptional modification are observed in vivo, in the brains of AD and Down’s 
syndrome patients 
457-458
 due to presenilin 1 mutations.
55a
 In particular, the 
aggregation of pGlu-A (3-42)
458
 and  pGlu-A (11-42) has been examined.
459
 These 
peptides exhibit accelerated aggregation compared to the unmodified A 40 and A 42 
and their possible role in seeding aggregation in vivo was noted.
459
 
 
The important role of the C-terminal hydrophobic domain, in particular A (34-42) in 
driving fibril formation has been examined.
34,372,460
  The length of the C terminus 
critically influences the rate of amyloid formation but only has a minor effect on the 
solubility.
34
 Peptides containing the C terminal sequence A (36-42/43) can seed 
fibrillization by peptides lacking the C terminal residues (A 40-42).
34
 
 
4.6 Micelles 
A  has surfactant-like properties, for example it is able to reduce surface tension in a 
concentration-dependent manner and both A 40 and A 42 and shorter variants (C-
terminal truncations) exhibit an apparent critical micelle concentration (cmc).
461
 The 
“micelles” may in fact correspond to proto-fibrillar species believed to be involved in 
the nucleation of fibril formation (section 4.3.1). The formation of SDS-stable 
aggregates was also confirmed by SDS-PAGE. For a series of C-truncated peptides, 
the cmc was found to be 25 M in aqueous solution, and measurements on the 
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partitioning of a fluorescent dye DPH (1,6-diphenyl 1,3,5-hextriene) suggested that 
residues 29-42 form the interior hydrophobic domain.
461
 The cmc of A 40 has also 
been deduced from the concentration dependence of fibril growth kinetics and was 
found to be c* = 0.1 mM in acidic aqueous solution.
400
 Surface-pressure area 
experiments and pyrene fluorescence measurements indicate c* = 17.5-17.6 M in 
aqueous Tris buffer solution.
462
 Wetzel and coworkers report a value c* = 0.7 – 1 M 
in aqueous PBS solution, measured by SPR and also deduced from fibril dissociation 
equilibrium constants, obtained from kinetic measurements of ThT fluorescence.
420
 
Linse et al. obtained c* =  0.2 M for A (M1-42) in the buffer system they studied, 
and noted that this is lower than the value observed by Wetzel and coworkers for 
A 40 due to differences in ionic strength of buffer as well as the peptide length.
408
 
The aggregation number of the micelles (N = 25) was estimated using fluorescence 
quenching techniques. The cmc of A (11-25) determined from FRET experiments is 
3 M at pH 5 and 70 M at pH 7.4.
463
 
 
Above the cmc, Lomakin et al. found that the initial rate of elongation and the final 
size of fibrils were independent of A  concentration due to the monomer-micelle 
equilibrium.
400
 The surfactant n-dodecylhexaoxyethylene glycol monoether (C12E6) 
slowed nucleation and elongation of A 40 fibrils in a concentration-dependent 
manner.
400
 The hydrodynamic radius of the micelles was approximately 7 nm. 
Detailed SANS experiments later provided a model for the shape and dimensions of 
“spherocylindrical” micelles.464 The authors identified these species as aggregates 
comprising 30-50 monomers, therefore they seem to correspond to proto-fibrils rather 
than oligomers.  
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SDS micelles hinder the formation of -sheet fibrils by A 40 and A 42, and instead 
stabilize helical conformations.
373
 However, at lower concentration (below the cmc), 
SDS promotes the formation of oligomers by A 42 (not A 40).
465
  The interaction of 
A 40 with SDS has been investigated by small-angle X-ray and neutron scattering 
(SAXS and SANS).
466
 It was shown by time-resolved SAXS that A 40 rapidly forms 
a complex with pre-existing SDS micelles due to interaction between the sulfate 
groups and the hydrophilic headgroup units of the surfactant.
466
 Below the critical 
micelle concentration of SDS, globular core-shell aggregates were also formed but 
lagging behind the CD-observed transition in secondary structure of A 40 from 
random coil to (predominantly) -helical. These measurements also showed that 
aggregation of A 40 in the presence of HCl can be monitored by SAXS. Aggregates 
of A 42 with SDS (sub-micellar concentrations) have been observed via AFM, and 
the effect of SDS on secondary structure was probed by CD and FTIR.
467
 The cationic 
surfactant hexadecyl-N-methylpiperidinium bromide is able to inhibit A  aggregation 
well below its cmc, pointing to a mechanism not involving micellar solubilisation.
468
 
A similar phenomenon is reported for a tetrameric quaternary ammonium cationic 
surfactant which can also disassemble existing A 40 fibrils.
469
 Instead, it was 
suggested that a specific binding surface on A 40 (absent for other amyloid forming 
proteins) is able to bind such amphiphilic molecules.
468
 A cationic surfactant 
containing an azobenzene moiety influences A 40 fibrillization differently depending 
on its conformation, which can be photo-switched.
470
 The interaction of A (12-28) 
with SDS has been investigated by CD and NMR, an -helical conformation for 
residues 16-24 was noted (see also section 4.1).
374
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The interaction of A 40 with the bio-derived surfactant surfactin is also dependent on 
the aggregation state of the surfactant.
471
 Below the cmc, surfactin causes A 40 to 
unfold and to fibrillize. Well above the cmc, -sheet fibril formation is inhibited. 
 
4.7 Interactions with Lipid Membranes 
 
The importance of lipid interactions with A  is highlighted by the fact that ApoE, 
(especially the 4 allele) a key genetic risk factor for AD (section 2.1), is involved in 
lipid metabolism.
472
 Lipid membranes have a number of important roles in 
modulating amyloid fibrillization. These include: (partially) unfolding the peptide, 
increasing the local concentration of peptide bound to the membrane, orienting the 
bound protein in an aggregation-prone manner and variation of penetration depth into 
the membrane affecting the nucleation propensity.
473
 Lipid rafts are implicated in A  
dimer and oligomer formation.
474
 and may provide platforms for selective deposition 
of different A  aggregates (this also depends on the ordering of the lipids within the 
membranes which may be different in the rafts
475
).
476
 Ganglioside-rich lipid rafts 
induce A  oligomerization, for which cholesterol appears not to be essential.
474b
 The 
involvement of different types of membrane structure (vesicles formed by different 
phospholipids and gangliosides) in A  fibril growth has been discussed in reviews of 
membrane-amyloid interactions.
224g,473,477
 The role of membranes in the formation of 
annular structures that may comprise arrays of oligomers has been revealed by 
AFM.
224g,226
 and the role of oligomers in creating pores/ion channels has been 
revealed by membrane conductance measurements (see also section 2.7).
215a
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A  is generated via regulated intramembrane proteolysis (RIP),
6e
 which involves the 
shedding of the ectodomain of APP through membrane-anchored secretases (section 
2.2.3). The membrane-bound stubs can then be cleaved within their transmembrane 
domains to release small peptides (A  in the case of APP) into the extracellular space 
and intracellular domains into the cytoplasm.
6e
 
 
A  which is a cationic peptide at neutral pH, (residue-specific pKa values are 
available
374,478
) interacts with anionic lipid membranes through electrostatic 
interactions, depending on pH.
224g,477a
 On the other hand, it has been reported that A  
can interact with cationic or zwitterionic lipids as readily as anionic lipids.
479
 This 
suggests that association of A  with lipid membranes is driven to a substantial extent 
by hydrophobic interactions with hydrophobic regions in the peptide. Preferential 
incorporation of A  into anionic lipid membranes is however noted.
480
 The interaction 
of A  with negatively charged lipids is driven by electrostatic interactions whereas 
insertion into the membrane is driven by the hydrophobic tail of A . It has been 
demonstrated that A 40 spontaneously inserts into anionic DPPG (1,2-dipalmitoyl 
phosphatidylglycerol) membranes but not zwitterionic DPPC (1,2-dipalmitoyl 
phosphatidylcholine) membranes.
481
 Furthermore, the DPPG membrane induces -
sheet “crystallization” of A ,481 although this interaction was eliminated above pH 7.4 
where A  becomes anionic. Enhanced binding of A 40 (tryptophan labeled Y10W 
for fluorescence experiments) oligomers to vesicles has been observed when DPPG is 
incorporated as compared to pure DPPC vesicles.
482
 Terzi et al. studied A (25-35) 
[and A (25-35Nle)] on anionic lipid membranes and noted an increase in -sheet 
formation (in solution both random coil and -sheet structures coexist for this peptide) 
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as probed by CD spectroscopy, in the presence of the negatively charged vesicles.
483
 
These authors were also able to measure binding enthalpies.
483
 The C terminus capped 
version of this peptide however adopts a random coil structure on binding to the lipid 
vesicles, pointing to the role of electrostatics in the binding process, also confirmed 
by salt screening experiments.
483
 This group found that A  can insert into anionic 
monolayers at sufficiently low packing density.
480
 These authors also noted transitions 
in secondary structure random coil – -sheet – -helix depending on the lipid-to-
peptide ratio.
480
 A shift to an initial -helical conformation has been noted upon 
binding of A  peptides to membranes,
374
 however the enrichment of peptide 
concentration close to the membrane may subsequently favour -sheet 
formation.
224g,477a
 Thus, membranes can inhibit fibrillization at high lipid-to-peptide 
ratio, but accelerate it at low relative lipid concentration.
224g
 Biological lipids (in 
liposomes) can resolubilize A 42 fibrils, and convert them into more toxic oligomeric 
forms, and the potential biological relevance of this was noted.
484
 
 
A  can form cation-selective channels when incorporated in lipid bilayers as revealed 
by conductance measurements.
225a-c,485
 A  peptides disrupt membranes comprised of 
negatively charged phospholipids, in a pH-dependent manner (which is important in 
the context of different pH levels in endosomes vs. the extracellular matrix, for 
example).
486
 AFM shows the formation of channel structures by A 42 reconstituted in 
planar lipid bilayers.
226a
 On the other hand, Kayed et al. report that A  oligomers 
increase permeability (quantified via conductance measurements) without any 
evidence for pore formation or ion selectivity.
215a
 Serpell and coworkers have 
observed that the A  aggregation state influences its ability to permeate vesicles 
(probed via calcein fluorescence measurements), and that oligomers have the highest 
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membrane disruption activity.
487
 The less fibrillogenic A 40 has a reduced tendency 
to permeabilize membranes than A 42. The role of GM1 ganglioside receptors was 
also highlighted.
487
 
 
Nussinov and coworkers have performed MD simulations of A  in lipid bilayers, 
focussing on A (17-42) protofibrils, and A  pore structures were examined.
366,488
 The 
formation of subunit structures within the channels was observed.  The selectivity of 
the channels for Ca
2+
 observed experimentally was also confirmed from the 
models.
488
 Consistent with AFM images of A 40 in a DOPC (dioleoyl 
phosphatidylcholine) bilayer,
226b
 break-up of the channels into subunits was observed 
(Fig.26). 
488
 Strodel et al. have also performed MD simulations on A  pore structures, 
for A 42, modeling oligomers.
489
 They found that membrane-spanning -sheets adopt 
ordered configurations for dimers to hexamers, however separation into subunits was 
only observed for octameric oligomers which separated into distinct subunits (cf. 
Fig.24).
489
 A molecular dynamics simulation of the interaction between A 42 and 
zwitterionic and anionic lipids indicated that peptide-peptide interactions are favoured 
in the vicinity of the membrane, driving oligomerization in the case of the anionic 
lipid membranes.
490
 The dependence on pH was also modelled. 
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Fig.26. MD simulation of a 24-mer channel formed by A (17-42) in a DOPC lipid 
bilayer.
366,488
 The yellow numbers label sub-units. Reprinted from Jang, H. B. et al. 
Trends in Biochemical Science 2008, 33, 91, Copyright 2008, with permission from 
Elsevier. 
 
 
The binding of A  and gangliosides [ganglioside = glycosphingolipid] has been the 
subject of several studies, although with conflicting conclusions.
477a,491
 Ganglioside 
membranes have been reported to accelerate A  aggregation
300,474c
 or to inhibit it and 
stabilize -helical structures
492
 or to induce -sheet structure.
493
 Another report claims 
that gangliosides induce A  to adopt a mixed /  conformation at neutral pH.486 
Actually, a transition from random coil to -helix might be favoured at low peptide-
ganglioside lipid ratios, whereas higher ratios promote the adoption of a -sheet 
conformation.
224g,493b
 It has been proposed that ganglioside clusters may form sites 
that seed A  fibril formation.
224g,477a
 The interaction of A 40 and A 42 with 
phosphatidylinositol (PI) with different inositol headgroups was examined.
276
 The 
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formation of -sheet structures was found to be pH-dependent in the presence of PI 
vesicles – both A 40 and A 42 aggregate at pH 6 (close to the pI = 5.5)491,494 but only 
A 42 aggregates at pH 7. The work with different PI vesicles formed part of the basis 
for the development of an inositol-based inhibitor of A  aggregation,
276
 as discussed 
further in Section 3.2.1. formation of A 40 fibrils is accelerated in the presence of 
ganglioside-containing POPC (1-palmitoyl-2-oleoyl phosphatidylcholine) 
vesicles.
300,495
 The binding of the peptide to the membrane was analysed 
quantitatively. The binding was found to be ganglioside-specific.
300,495
 AFM and 
TEM imaging show aggregation and fibril formation of A 40 and A 42 on total brain 
extract lipids.
496
  
 
Bokvist et al. used MAS-NMR (MAS: magic angle spinning) and CD to probe the 
interaction of A 40 in different lipid membranes.
497
 Charged membranes can act as 
templates for aggregation of surface-associated A 40 in the case that the peptide is 
released in soluble form. However, membrane inserted A 40 is anchored by the K28 
residue by electrostatic interactions with negatively charged lipids.
497-498
 By studying 
a series of full length peptides and fragments, Chauhan et al. were able to highlight 
the role of aliphatic residues at the C terminus of A  interacting with the fatty acid 
chains as well as the electrostatic interaction involving K28.
498
 Several groups have 
noted that the interaction of A  with membranes depends on the ordering of the lipid 
membranes.
479b,499
 Murphy and coworkers used fluorescence anisotropy of an inserted 
probe to examine interaction of A 40 with lipid membranes.
479b,491
 They observe that 
A  aggregates only affect lipid membrane fluidity above, and not below, the lipid 
chain melting temperature.
479b
 Aggregated A  decreases membrane fluidity, but A  
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monomer does not. Aggregation rate and surface hydrophobicity were greater for 
A 40 prepared at pH 6 compared to pH 7.
491
 However, Wood et al. observe that 
A 40 does not form amyloid fibrils at pH 5.8 (approximate pH of endosomes and 
conditions for proteolytic cleavage), but rather forms larger aggregates which lead to 
turbidity of the solution.
422
 Inhibition of A  fibril formation was observed to depend 
on the state of the lipid membrane in studies of the interaction of A (M1-40) and 
A (M1-42) (recombinantly expressed in E. Coli, Section 2.2.2) with liposomes.
499
 
The largest retardation is observed when DPPC bilayers are in the solid gel phase. 
The mobility of A 42 prefibrillar and fibrillar oligomers on the membrane of living 
cells or lipid membranes has been investigated via single particle tracking techniques 
(using quantum dots as labels).
500
 The dynamic behaviour is distinct depending on the 
aggregation state (and conformation) of the peptide, although motion for oligomers is 
largely confined. Diffusion coefficients were obtained and differ significantly for 
fibrillar and prefibillar oligomers recognized by the A11 antibody.
500
 
 
The insertion of the transmembrane fragment A (25-35) into phospholipid bilayers 
has been examined by neutron diffraction using deuterium labeling techniques.
501
 The 
location of the peptide C terminus was studied in two different lipid compositions and 
was found to be dependent on the surface charge of the membrane (zwitterionic or 
anionic). The adsorption of A 40 on phospholipid monolayers has been probed using 
grazing incidence x-ray diffraction and IRRAS.
502
 On negatively charged monolayers, 
the peptide adsorbs at the air-water interface and inserts into the monolayer, although 
it is squeezed out at high surface pressure. A 40 can also penetrate into disordered 
anionic monolayers in buffer due to salt screening of electrostatic interactions.
502
 The 
influence of A (25-35) and A (22-40) on the picosecond dynamics of lipid 
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membranes has been examined by quasi-elastic neutron scattering.
503
 The main 
influence was on long-range translational diffusion, although localized diffusion was 
also considered. By selection of the A (11-22) fragment, the role of charge, and the 
influence of pH, in governing the interaction of A  with lipids was examined.
504
 Only 
at endosomal pH (approximately 6) does the peptide insert into negatively charged 
membranes, with a conformation change (increase in -helix content in the presence 
of lipids) detected by CD. Specifically, the protonation state of H13 and H14 was 
found to be important (as in the case of interactions with metal ions, section 4.8).
504
 
 
Aggregation of A 42 proceeds with distinct aggregate morphology (and kinetics) 
when adsorbed on hydrophilic mica or hydrophobic graphite.
505
 and this was related 
to fibrillization at interfaces such as membranes. 
 
The role of cholesterol in AD has been examined due to the mutal interaction of A  
and cholesterol (the metabolism of which is modulated by ApoE).
472a,474c,477a,506
 
Cholesterol mediates A  aggregation and reciprocally A  influences cholesterol 
dynamics in neurons, leading to tauopathy.
472a
 Whether cholesterol inhibits or 
promotes A  fibrillization may depend on its content within the membrane,
224g,507
 and 
the presence of metal ions.
508
 Serum and CSF levels of cholesterol may provide a 
biomarker for AD (others are discussed in Section 2.4) although the relationship 
between HDL (high density lipoprotein) level and AD is not clearly established at 
present.
472a
 A correlation between cholesterol (uncharged) content in the model 
membranes and A 42 deposition was noted, due to the effect of cholesterol on 
membrane rigidity (addition of A 40 increased vesicle rigidity).
496a
 The structure of 
lipid membranes extracted from AD patient brain tissue has been compared to control, 
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using SAXS to obtain electron density profiles and differences were ascribed to the 
increase in cholesterol level in the AD brain.
509
 The changes in membrane rigidity in 
turn influence Ca
2+
 ion transport across neuronal cell membranes.
485
 An inverse 
correlation between membrane cholesterol level and A -cell surface binding and 
cytotoxicity was observed.
496a
 The role of cholesterol in amyloid aggregation and tau 
phosphorylation has been reviewed. 
472,510
 Statins may have a role in alleviating AD 
pathologies associated with cholesterol since they can influence cholesterol 
metabolism in the human brain. 
472a,506,511
 Several cholesterol derivatives have been 
found to enhance A 42 fibrillization, and aspirin can inhibit this cholesterol-mediated 
fibrillization.
512
 The formation of the GM1 ganglioside-bound A  (GM1/A ) 
complex (found in the brains of AD patients and proposed to seed A  aggregation) is 
cholesterol-dependent.
513
 Cholesterol byproducts from antibody-induced ozonolysis 
during inflammation have been detected in human brains.
514
 These compounds which 
contain aldehydes dramatically accelerate A  aggregation in vitro. The authors note 
that these observations relate to some common features of AD and atherosclerosis, in 
particular in terms of inflammation.
514
 The mechanism of interaction of these 
cholesterol metabolites with A 40 was subsequently analysed in detail.
515
 
 
 
4.8 Effect of Metal Ions 
 
 
Aggregation of A  may be promoted by metal ions.
16d,516
 High concentrations of 
metal ions (Cu
2+
, Fe
3+
, Zn
2+
, Al
3+…) are found to be co-localized at abnormally high 
concentration with senile plaques in AD brains.
517
 A  rapidly aggregates in the 
presence of physiological concentrations of Zn
2+
 at pH 7.4.
106b,518
 Enhanced Cu
2+
-
induced aggregation is noted when the pH is lowered to 6.8.
518b
 Mildly acidic 
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conditions are often associated with inflammation. APP binds copper in the N 
terminal domain within the APP(135-175) sequence.
16d
 The copper binding domain 
contains a His-X-His motif.
16d
 Metal ions are involved in processes associated with 
inflammation in AD patients (vide infra). Treatment with metal ion chelators can 
reduce the deposition of A  in brains, as discussed further in section 3.2.1.
242a,242d,259
 
The focus of most studies has been Cu
2+
, Zn
2+
 Al
3+
 and Fe
3+
, which enhance fibril 
formation.  
 
Transition metal ions may interfere with transport across ion channels, eg. Al
3+
 
ions
225a
 and Zn
2+ 
ions
225d,226a,229,266b
 have been shown to block these channels. In the 
latter case, this can be reversed using a Zn
2+
 chelator.
225d
 Arispe et al. also point to the 
formation of channels in bilayer membranes as a possible tool to screen for possible 
therapeutic compounds.
225a
 Zn
2+
 and Cu
2+
 ions induce A 42 and A 40 insertion into 
vesicles in a suitable pH range with an accompanying formation of -helical 
structures.
508
 
 
Surface plasmon resonance (SPR) biosensing has been used to investigate the 
aggregation of A 40 in the presence of Cu
2+
, Ca
2+
, Fe
2+
 and Fe
3+
.
519
 All ions 
promoted A  aggregation, but with different rate constants, that for Cu
2+
 being 
highest, although the aggregates were unstable. The chelator EDTA (ethylenediamine 
tetraacetic acid) can dissociate metal-ion induced A  aggregates.
519
 Rottkamp et al. 
showed that if A  is pretreated with the iron chelator deferoxamine, neuronal toxicity 
is significantly reduced while conversely, incubation of A  with excess free iron 
restores toxicity to original levels.
520
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The aggregation of human A  is stimulated by the presence of zinc ions at sufficiently 
high concentration due to binding mediated by histidine.
106b
 The importance of the 
H13 residue in A  in binding Cu
2+
 and Zn
2+
 in a pH-dependent manner was 
highlighted (the other N terminal histidines H6 and H14 also play a role).
259b,518b,521
 
The Cu
2+
 binding site can also involve D1 or E11.
522
 A solid state NMR study has 
recently elucidated the Cu
2+
 binding site of A 40.
523
 It was reported that under 
physiological conditions, aluminium, iron, and zinc strongly promote A  aggregation 
(rate enhancement of 100-1,000-fold) whereas the other metal ions (including 
calcium, copper and sodium) studied do not.
524
 The aggregation of A  induced by 
iron or aluminium ions is distinguished from that of Zn
2+
 by its rate, extent and pH- 
and temperature-dependence as probed via sedimentation experiments using 
125
I-
labelled A (1-40).
524
 It has been proposed that rapid formation of a pre-oligomeric 
peptide/metal/peptide complex follows binding of Cu
2+
 to A , leading to inhibition of 
oligomer formation,
525
 as observed at low Cu
2+
 concentration.
526
Ascorbate-dependent 
hydroxyl radical generation, is inhibited by A (1-16) or A 42 for Cu
2+
 or Fe
3+
.
521e
  
 
AFM imaging directly illustrates the influence of copper and zinc ions on the 
aggregation of A 42, preventing fibrillization even in trace amounts.
527
 Using 
immobilized A  seeds (Section 4.3.1), Cu
2+
 and Zn
2+
 at neutral pH are found to 
accelerate the deposition of A 40 and A 42 but produce amorphous aggregates 
whereas Fe
3+
 induces the formation of fibrils.
418b
 The effects of mixtures of Cu
2+
, Zn
2+
 
and Fe
3+
 ions on A 42 aggregation has also been examined via AFM using the same 
technique. 
528
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The role of aluminium in the etiology of AD is controversial.
516d,529
 It was originally 
found to be associated with plaques in AD patients, in the form of aluminosilicates
530
 
specifically associated with neurofibrillary tangles.
529b,531
 Aluminium has significantly 
higher cytotoxicity in complexes with A 42 than Cu
2+
, Zn
2+
 and Fe
3+
 and the 
aggregation properties of A  in the presence of Al
3+
 are also substantially different.
532
 
 
The effect of metal ions on A  aggregation has been correlated to oxidative 
stress.
517b,520
 Both iron and copper have high affinity for A  and are reduced by it, 
with the subsequent production of hydrogen peroxide and oxidised A .
533
 Iron has 
been implicated as a key species in oxidative stress, due to its involvement in the 
creation of free radicals (in particular hydroxyl radicals
517b
) from H2O2 via the Fenton 
reaction.
534
 It has been suggested that iron enhances the toxicity of A  by delaying the 
deposition of the peptide into well-defined fibrils.
535
 The cytotoxic effects of A  can 
be attenuated by antioxidants and free radical scavengers such as vitamin E. 
 
 
The zinc binding motif, strongly conserved among members of the APP family has 
been identified.
536
 APP can catalyze the reduction of H2O2 and ensuing oxidation of 
Cu
+
 to Cu
2+
 in a peroxidative reaction in vitro, leading via a Fenton-type reaction to 
free radical formation.
536c
  
 
 
4.9 Conjugates of A  with Polymers and Lipid Chains 
Conjugation of peptides to synthetic polymers such as PEG may lead to improved 
solubility, enhanced stability against dilution, reduced toxicity and 
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immunogenicity.
537
 The solution self-assembly of peptide-containing copolymers has 
been reviewed.
538
 
 
In a pioneering series of papers, Meredith and coworkers have confirmed the 
formation of fibrils in aqueous solutions of PEG-peptide diblocks where the peptide 
block was based on the central hydrophobic domain A (10-35) of the -amyloid 
peptide and the PEG block had a molar mass of 3000 g mol
-1
.
539
 They found from 
SANS and TEM that the PEG forms a coating around the fibril, thus acting as a 
“steric stabilization” layer. The self-assembly in aqueous solution of PEG-peptides, 
with peptide sequences based on KLVFF A (16-20) motif has been investigated, with 
PEG molar mass in the range 1000 – 3000 g mol-1. Conjugates FFKLVFF-PEG540 and 
YYKLVFF-PEG
541
 form core-shell fibrils and aggregation into nematic and 
hexagonal columnar liquid crystal phases is observed at high concentration. 
Conjugate A AKLVFF-PEG was used in studies of enymatic cleavage (using -
chymotrypsin to cleave between the two phenylalanine residues).
542
 The conjugate 
forms spherical micelles which are degraded by the enzyme, releasing peptide 
A AKLVF (which does not aggregate into amyloid). 
 
The formation of amyloid-like structures at the air/water interface was reported for 
peptide amphiphiles (PAs) with a peptide sequence based on A (31-35), i.e. IIGLM, 
attached to a C18 chain.
543
 Epifluorescence microscopy showed the formation of 
threadlike and needle-like aggregates. Yilin Wang’s group have shown that PA C -
A (11-17) forms fibrils.
544
 The double tail analogue PAs 2C12-Lys-A (12-17) and 
C12-A (11-17)-C12 self-assemble into fibrils or twisted ribbons/tapes respectively, the 
latter dependent on pH.
545
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5. SUMMARY AND OUTLOOK 
 
This review has focussed on the biological and biophysical properties of the Amyloid 
 (A ) peptide and its role in Alzheimer’s disease. The biological, biochemical and 
neurochemical characteristics of AD, involving A  and APP have been discussed. 
Therapeutic treatments including those on the market, or those that have been or 
continue to be the subject of clinical trials have been described. Finally, aspects of the 
biophysical chemistry of A  and A  fragment peptides have been outlined, including 
various aspects of structure at the molecular and supra-molecular level, and 
aggregation mechanisms and kinetics. 
 
It is now more than a century since Alzheimer identified the disease now named after 
him, and more than a quarter century since aggregation of amyloid beta peptide was 
first associated with the condition. As a major global healthcare challenge, there has 
been intense research activity in this period. This has led to deep insights into the 
causative agents, the current consensus being that A  is the primary suspect. 
However, the progression of AD is not straightforward, and other factors are almost 
certainly involved, including other proteins such as tau, but also influences such as 
oxidative stress. Further large-scale genetic and proteomic screening studies will 
almost certainly reveal other risk factors.   
 
A number of compounds are available to amelioriate the early stage symptoms of AD, 
however there is still no effective treatment that can halt or reverse progression into 
the debilitating late stage of the disease. Several approaches have led to compounds 
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that have reached phase III clinical trials, some of which failed. However, given the 
complexity associated with treatment of brain disease and the fact that it involves a 
subtle target, i.e. a protein misfolding process, some setbacks along the road are 
probably inevitable. The problem of finding a selective therapeutic agent is 
challenging given the diversity of biochemical pathways involved in brain signalling 
and other neuronal growth and differentiation processes. Nonetheless, there is reason 
for optimism as clinical trials of a number of therapeutic agents continue. There has 
been some refocusing by big pharma in the brain (and central nervous system) disease 
field, but some significant players are still very active in R&D related to AD 
therapies. Furthermore, governments internationally are increasingly recognising the 
magnitude of the problem of diseases of aging, especially AD, and there is currently 
substantial investment in further research through various funding agencies and 
networks. Probably closer to realisation are effective diagnostic systems based on 
blood or plasma analysis, or brain scanning methods. 
 
In terms of biophysical measurements, it has to be noted that A  is a difficult peptide 
to work with, in the sense that its aggregation properties are highly sensitive to 
sequence, purity and preparation conditions. The latter include initial dispersal 
solvent, nature and concentration of the aqueous or buffer solutions, but also the 
effect of shear during mixing and potentially the nature of the surface of the vessel. 
Small differences in preparation conditions can lead to distinct polymorphs, which 
can propagate, as discussed in section 4.4. 
 
Despite these caveats, there is now a great wealth of data on the fibrillization 
properties of A , variants and fragments under defined conditions. These 
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measurements provide a strong framework to underpin the ongoing biological 
research activity. 
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